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Nasopharyngeal carcinoma (NPC) is a rare disease in the Western
world, but it is endemic in certain parts of Southeast Asia and China.
During the last decades, the outcome of the treatment has improved
considerably. Concurrent chemo-radiation has become the treatment
of choice in advanced NPC. Five years survival figures of 80-90 % for
T1-T2 and 60-80 % for T3-T4 are not exceptional. The relation be-
tween NPC and the Epstein Barr virus (EBV), which is almost 100 % in
endemic areas, has opened up several possibilities for early detection
and monitoring of the disease using EBV based markers or to new
treatment strategies based on this viral connection.
The main progress in the treatment of NPC is coming from the top
end hospitals in the high endemic regions. Effective treatment
schedules are applied and compliance with treatment and follow up
are secured. The good news is the fact that the incidence of NPC is
also declining in more prosperous cities like Hong Kong and
Singapore and the big cities in Taiwan. So, apparently, preventive
measures can be effective on the long term.
Unfortunately, NPC is correlated to hygiene and environmental cir-
cumstances like pollution in areas where those being treated live,
the adding of carcinogens to food and even to candies and it is
more common in developing countries where many patients are suf-
fering from this disease. Furthermore, the treatment possibilities in
these parts of the endemic regions are less favorable. Due to the
shortness of radiotherapy capacity and the lack of adequate insur-
ance systems, many patients do not have access to effective treat-
ment for this disease.
In a recent study in a tertiary referral hospital in Yogyakarta, the
treatment results appeared to be behind compared with the inter-
national literature. Waiting time for radiotherapy was during the
years of the study (2009-2013) between 3 and 4 months, but has in-
creased to over 1 year and 9 months in March 2015, probably due to
the introduction of the National Healthcare program in Indonesia.
The most obvious solutions would be to increase the number of RT
devices.
However, the short supply is so serious that at least 10 to 20 years
will pass before the capacity will be in line with the demand. In the
meantime patients are suffering and dying of this treatable disease.
Action is needed and preventive measures have to be taken.
Future research should focus on innovative treatment strategies like
photodynamic therapy, which have been proven to be effective in
residual or recurrent NPC. A combination with other novel treat-
ments, like vaccination and immunotherapy is challenging.© 2016 The Author(s). Open Access This artic
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The international geographic distribution of NPC is unique among
malignancies. Incidence rates can exceed 20 per 100,000 person-
years among males and 10 per 100,000 person-years among females
in southern China. Intermediate rates are observed in Southeast Asia,
North Africa, the Middle East, and the Arctic, as well as among Asian
and Pacific Islander migrant populations, while rates generally remain
below 1 per 100,000 throughout the rest of the world. The age-
specific incidence rate peaks at around 45-59 years in high-incidence
areas, whereas a small early incidence peak at ages 15-19 years is
followed by a later peak at around 65-79 years in low-incidence
areas. The male-to-female incidence ratio is consistently around
2-3 or greater. Much of the striking geographic variation may be
attributable to certain risk factors, such as certain HLA alleles and
consumption of Chinese-style salted fish, whose geographic dis-
tribution mirrors that of NPC. Other NPC risk factors, such as EBV
infection, are ubiquitous, yet are almost certainly modified by geo-
graphically heterogeneous co-factors. Most established risk factors
for NPC are associated with undifferentiated NPC, although to-
bacco smoking is more strongly associated with squamous cell
NPC. The recent worldwide decline in NPC incidence, especially in
high-incidence regions, points to an important role of modifiable
environmental risk factors that could serve as targets for further
disease prevention.I2
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Nasopharyngeal carcinoma (NPC) has a striking geographical vari-
ation with the highest incidence in South China, Southeast Asia, and
East Africa; and the lowest incidence in Europe, West Africa, and
Central America. As infection of Epstein-Barr virus (EBV), a well-
documented cause of NPC, is ubiquitous; the geographical variation
of NPC is likely attributable to ethnic and environmental cofactors.
Chinese ethnicity in almost all cancer registries in the world has the
highest incidence of NPC. Both case-control and cohort studies hasle is distributed under the terms of the Creative Commons Attribution 4.0
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mon environmental and genetic components shared by family mem-
bers may play a role in the development of NPC. Several molecular
and genomic biomarkers for the early detection or long-term risk
prediction of nasopharyngeal carcinoma have been reported previ-
ously. Elevated serotiter of antibodies against EBV including anti-EBV
VCA IgA, anti-EBV DNase, anti-EBNA1 and the elevated serum level of
EBV DNA (viral load) are the most important biomarkers for the
detection and prediction of NPC. Genetic polymorphisms of xeno-
biotic metabolism enzymes CYP2E1, DNA repair enzymes hOGG1 and
XRCC1, and human leukocyte antigen (HLA) are also associated with
NPC risk. Among various risk calculators for NPC, those incorporating
EBV biomarkers have the highest area under the receiver operating
curve (AUROC). The AUROC remains low for risk calculators including
only family NPC history and/or genetic polymorphisms, suggesting
familial tendency and genetic susceptibility may not have validity
(sensitivity and specificity) high enough for the early detection or risk
prediction of NPC.
I3
Genetic susceptibility risk factors for sporadic and familial NPC:
recent findings
Allan Hildesheim (hildesha@exchange.nih.gov)
Infections & Immunoepidemiology Branch, DCEG, NCI, Bethesda MD, USA
BMC Proceedings 2016, 10(Suppl 1):I3
Along with Epstein-Barr virus infection, genetic susceptibility is be-
lieved to play an important role in the development of NPC. Early
studies of NPC genetics used targeted candidate gene approaches.
Those studies were successful at identifying Human Leukocyte Anti-
gen (HLA) genes as important determinants of NPC risk but findings
were largely inconsistent with respect to other genes hypothesized
to be involved in NPC pathogenesis. Technological advances have
allowed for more comprehensive approaches to query genetic fac-
tors linked to NPC development, using SNP-based genotyping and,
more recently, next generation sequencing approaches. Both spor-
adic and familial NPC studies have been conducted or are underway
using these newer technologies. In this presentation, findings and
ongoing efforts to characterize genetic risk factors for sporadic and
familial NPC will be presented and discussed. Most of these studies
have been conducted by collaborative groups, including the Inter-
national NPC Genetics Working Group for sporadic NPC and a NCI-
Taiwan collaboration for familial NPC.
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Incidence rates of nasopharyngeal cancer (NPC) vary markedly across
the world. In Sarawak, Malaysia incidence rates differ importantly be-
tween ethnic subgroups. This presentation will discuss both genetic
and environmental explanations for these incidence rates differences.
Germ-line exome sequencing within 12 NPC patients from a Bidayuh
pedigree identified haplo type sharing within the major histo-
compatability complex region on human chromosome 6. However, it
does not appear completely explain the segregation of NPC in the
pedigree. By contrast, important associations were noted with con-
sumption of preserved foods, for example frequent heavy consumers
of salted fish had an over 4-fold risk of NPC relative compared to
never consumers (p = 9x10-20). These associations were also more
marked within higher incidence rates ethnic subgroups. These resultssuggest that environmental exposures, rather than genetic suscepti-
bility, appear more likely to explain the heterogeneous incidence
rates in this region.
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NPC is a major tumor prevalent in South China including Hong Kong
and Southeast Asia, as the top cancer for males of 20-44 years of
age. Current genomic sequencing studies found only rare mutations
in NPC, indicating its critical epigenetic etiology. NPC is virtually
100 % associated with the infection of herpesvirus Epstein-Barr virus
(EBV), which is a strong epigenetic driver inducing more CpG methy-
lation in infected cells. Although multiple genetic/genomic studies
have shown numerous alterations of cancer genes in NPC, no epige-
nome study is available for NPC yet, except for some single-gene-
based epigenetic studies. We profiled the whole-genome CpG
methylation (methylomes) of NPC cell lines, primary tumors and nor-
mal nasopharyngeal epithelial cells (including EBV-infected ones)
using methylated DNA immunoprecipitation (MeDIP). We observed
extensive, genome-wide methylation of cellular genes, with methyla-
tion of multiple known and novel genes verified. In total, we identi-
fied ~1000-2000 methylated genes with promoter CGIs in cell lines
and primary tumors. Moreover, EBV-induced cellular gene methyla-
tion was also identified. Epigenetic disruption of key signaling path-
ways including Wnt, MAPK, TGF-beta, Hedgehog and ErbB signaling
was detected through bioinformatics analysis. Frequent methylation
of Wnt signaling regulators including SFRPs, DACTs, DKKs, WNT5A,
CDH11 and ROR2 was detected in cell lines and primary tumors. Fur-
ther functional studies showed that these genes are bona fide tumor
suppressor genes (TSG) for NPC. TSG methylation could also be de-
tected in nasal swab and serum samples from NPC patients, hence of
potential biomarker value. Thus, NPC methylome shows a special
high-degree CpG methylation epigenotype, similar to the EBV-
infected gastric cancer, indicating a critical role of epigenetic alter-
ations in NPC pathogenesis.
I7
Tumor exosomes and translational research in NPC
Pierre Busson1, Claire Lhuillier1, Olivier Morales2, Dhafer Mrizak2,
Aurore Gelin1, Nikiforos Kapetanakis1, Nadira Delhem2
1Université Paris-sud, CNRS UMR8126 and Gustave Roussy,
Villejuif, France; 2 Université de Lille, CNRS UMR 8161 and Institut Pasteur
de Lille, Lille, France
Correspondence: Pierre Busson (pierre.busson@igr.fr) – Université
Paris-sud, CNRS UMR8126 and Gustave Roussy, Villejuif, France
BMC Proceedings 2016, 10(Suppl 1):I7
Exosomes are extra-cellular nanovesicles of 50 to 100 nm in diameter
which are produced by all types of eukaryotic cells including cancer
cells and which play a key role in cellular communications. Prior to
their extra-cellular release, exosomes are formed in endosomal or-
ganelles called multivesicular bodies. Proteins carried by exosomes
are contained in their peripheral lipid bilayer or their internal cavity.
It is convenient to classify these proteins in three sets: a) structural
proteins common to all exosomes regardless of producing cells (for
example CD63); b) proteins related to a specific lineage of producing
BMC Proceedings 2016, Volume 10 Suppl 1 Page 3 of 24cells (for example CD227 or CD326 for epithelial cells), c) proteins
linked to a specific physiological condition (for example TSAP6 in
cells undergoing genotoxic stress).
Various nucleic acids are consistently carried by exosomes: micro-
RNAs, messenger RNAs, long non-coding RNAs and probably DNA.
There are now multiple evidences of horizontal genetic transfers me-
diated by exosomes in vitro and in vivo. Exosomes are involved in
various aspects of tumor biology, especially immune suppression,
preparation of the metastatic niche and angiogenesis. There are
three major reasons to investigate exosomes in NPC patients: their
probable contribution to oncogenesis, especially viral oncogenesis,
their role in immune suppression and their potential as a source of
biomarkers. For example, there is indirect evidence that LMP1 carried
by exosomes play a role in tumor angiogenesis. The immunosuppres-
sive functions of NPC exosomes have been recently documented
in vitro as well as in murine models.
Regarding the development of biomarkers, it is interesting to note
that specific capture of NPC tumor exosomes can be achieved from
plasma samples on the basis of their surface expression of HLA class
II molecules. One aim of future investigations will be to determine
whether exosome capture can improve detection of viral nucleic
acids in the peripheral blood (especially viral microRNAs).
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EBNA1 is the only EBV protein expressed in all EBV-induced tumours. It
contributes to latent EBV infection in multiple ways including manipula-
tion of the cellular environment in order to promote cell survival. One
way that EBNA1 manipulates cells is by binding and hijacking specific
host proteins, including casein kinase 2 (CK2), known to regulate mul-
tiple pathways important for cell proliferation. EBNA1 binds CK2
through its regulatory (β) subunit and can relocalize CK2 to promyleo-
cytic leukemia (PML) nuclear bodies where CK2 phosphorylation of
PML proteins leads to loss of the nuclear bodies, resulting in impair-
ment of apoptosis and DNA repair. Using a proteomic approach, we
identified an uncharacterized cellular protein (ARKL1) as binding CK2β
through the same binding pocket as EBNA1, suggesting that EBNA1
could interfere with ARKL1 function by blocking its binding to CK2.
One function we have identified for ARKL1 and CK2β is in inhibiting
the EBV lytic cycle. Therefore the interplay between EBNA1, ARKL1 and
CK2 may be one way of regulating EBV reactivation. We also used
miRNA cloning coupled with high throughput sequencing, to investi-
gate the effects of EBNA1 on cellular miRNAs in NPC cells. EBNA1 was
found to upregulate multiple let-7 family miRNAs, including let-7a. Con-
sistent with these effects, the let-7a target, Dicer, was decreased by
EBNA1, and reporter assays indicated that this effect was dependent
on the let-7a target sequences in the Dicer 3′UTR. Previous reports indi-
cate that low Dicer levels promote tumour metastases and the
epithelial-to-mesenchymal transition (EMT), and that EBNA1 induces
EMT in NPC cell lines. Therefore our results suggest that EBNA1 might
induce EMT by lowering Dicer. In addition, Dicer has been implicated in
promoting EBV reactivation. Accordingly, we found that a let-7a mimic
inhibited EBV reactivation to the lytic cycle while a let-7 sponge in-
creased reactivation. These results provide a mechanism by which
EBNA1 promotes EBV latency by inducing let-7 miRNAs.I9
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lignancy driven by Epstein-Bar virus (EBV) infection and cumulative
genetic and epigenetic changes. Both viral and cellular genes con-
tribute to disease pathogenesis and their interplay creates distinct
phenotypes, unique molecular features and tumor microenviron-
ment. Although few recurrent mutations in common cancer-related
genes were reported in the recent genomic studies, the contributions
of several unique somatic genetic changes in NPC tumorigenesis will
be discussed.
Our molecular and functional studies have revealed the high fre-
quency of genetic alterations in p16/CyclinD1 pathway and their
critical role in supporting stable EBV infection in NPC. In stably EBV-
infected cells, constitutive activation of multiple signalling pathways
by either latent viral oncoproteins, such as LMP1, or somatic changes
plays a crucial role for driving transformation. Activation of distinct
NF-κB signals, p50/p50/BCL3 and/or p50/RelB, are consistently found
in EBV-positive NPC tumor lines and primary tumors. Notably, recur-
rent somatic changes in multiple components (e.g. LTBR, TRAF3,
TRAF2, NFKBIA, A20) of NF-κB were detected in the tumors, especially
that with weak or absence of LMP1 expression. These mutational
events enhance cell survival and modulate tumor microenvironment
via constitutively activated NF-κB signals. The unique finding high-
lights the importance of inflammation in NPC tumorigenesis. Further-
more, inactivating TRAF3 by LMP1 and somatic mutations may allow
NPC cells to evade immune response against abundant EBV-encoded
transcripts such as EBERs. On the other hand, by next generation se-
quencing, we recently identified a number of fusion transcripts in a
panel of EBV-positive NPC tumor lines. Among these gene rearrange-
ments, a novel fusion gene UBR5-ZNF423 is recurrently detected
in >8 % of primary tumors. Notably, the growth of NPC cells with
UBR5-ZNF423 rearrangement is dependent on expression of this
fusion gene. The transforming ability of UBR5-ZNF423 fusion was
also confirmed by in vitro and in vivo studies. Constitutive expres-
sion of UBR5-ZNF423 in NIH3T3 fibroblasts significantly enhanced
its anchorage-independent growth in soft agar and induced tumor
formation in a nude mouse model. These findings suggest that ex-
pression of UBR5-ZNF423 might contribute to the transformation of
a subset of NPCs, possibly by altering the activity of early B cell fac-
tors (EBFs).
Finally, it is believed that comprehensive characterization of the NPC
genome by multiple sequencing platforms might unveil more critical
genetic changes contributed to the progression of this EBV-associated
epithelial malignancy.
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A cluster randomized nasopharyngeal carcinoma (NPC) mass screen-
ing trial using a combination of immunoglobulin A antibodies
against Epstein-Barr virus capsid antigen (VCA/IgA) and nuclear
antigen-1 (EBNA1/IgA) by enzyme-linked immunosorbent assay
(ELISA) has been conducted in Zhongshan and Sihui cities in South-
ern China. The residences aged 30-59 years in the 8 screening towns
of the 2 cities were invited to participate in this screening trial from
2008. Until the end of 2012, a total of 45,005 participants were re-
cruited. In this study, we showed NPC cancer occurrence and the
early detection rates in the population of the screening towns com-
pared with those in the control towns. After more than 1 year follow-
up, 89 NPC cases (with 4 cases unknown clinical stage) were de-
tected in all of the screened participants, 76 cases (with 16 cases
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screened town and 69 (with 8 cases unknown clinical stage) in
one control town. The corresponding early detection rates in the
screened participants (63/85, 74.1 %) was 3.5 times higher than that
in the population of the control town (13/61, 21.3 %), p < 0.001. In
the screened towns, about 36.9 % target participants took part in the
screening trial and the early detection rates in the screened partici-
pants was also higher than the non-participants (13/60, 21.7 %), p <
0.001. Moreover, most of the NPC patients (71/89, 80.0 %) were de-
tected in the high risk group, next in the medium risk group (12/89,
13.5 %) and the lowest in the lowest risk group. In the 28,688
screened participants with follow-up more than 3 years, the serial de-
tection for NPC cases was also analyzed annually. The results showed
that 60 % NPC cases (61.7 %, 42/70) were detected in the first year
follow-up; however, the cancers were rare in the low risk group in
the 3 years of follow-up. It suggested that NPC screening with ELISA-
based EBV antibodies could increase the early detection rate of NPC
in the screening group and further follow-up is needed to examine
whether screening had an effect on decreasing mortality for NPC in
endemic areas.I11
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Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma
which is sensitive to treatment when detected early, but early detec-
tion of NPC has proven difficult due the location of the tumor and
the lack of obvious clinical signs. Hence, there is a need for a sensi-
tive and specific biomarker for early stage or occult NPC. Epstein Barr
Virus (EBV) has been implicated as an active player in NPC pathogen-
esis. Elevated IgA antibodies to a number of EBV antigens occur in
the vast majority of individuals with frank NPC, and antibody titers
tend to rise with tumor burden and correlate strongly with tumour
remission and recurrence. Simplex ELISAs targeting anti-EBV EBNA1
and VCA IgA are highly “sensitive” to the presence of the tumor. In
fact, efforts are underway in some regions to evaluate EBNA1/VCA
IgA screening for the early detection of NPC. Predicted specificity of
these tests, however, is not optimal. We hypothesize that a whole
proteome microarray approach can be applied to identify a multi-
plexed antibody signature to EBV as a sensitive and specific bio-
marker for NPC. To test this hypothesis, we constructed a novel
protein microarray that contains the entire EBV proteome, repre-
sented by approximately 90 proteins derived from publically avail-
able prototypical EBV type 1 and type 2 genome sequences as well
as known splice variants of those proteins (approximately 200 pro-
tein fragments in total). This proteome microarray is being probed
with well-characterized serum samples from histologically confirmed
NPC cases and community-matched controls. Using comprehensive
feature selection analysis, we hope to identify an EBV antibody sig-
nature that effectively discriminates between NPC case and control
subjects. Such an antibody signature could be applied to screen pop-
ulations resident in areas where the incidence of NPC is high for po-
tential therapeutic intervention.I12
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Introduction Nasopharyngeal cancer (NPC) is common in Indonesia.
Nevertheless, most people are diagnosed with an advanced stage of
disease resulting in poor treatment outcome. Late stage diagnosis of
these patients is partly due to limited knowledge of the early symp-
toms of NPC among health care workers in the primary health care
centers (PHCC) and the referral system for NPC suspects. We estab-
lished the NPC awareness program, which aims to educate general
practitioners (GPs), midwives and nurses working in the PHCC. The
aim of this study was to evaluate the efficiency of this program on
the short- and long-term improvement of knowledge and referral of
NPC patients by PHCC staff.
Methods The awareness program consisted of twelve symposia, or-
ganized in Yogyakarta, Jakarta and East Java. They contained lectures
about the early symptoms and the risk factors of NPC, practical
examination and the referral system for NPC suspects. A representa-
tive GP from each PHCC was invited to participate. Based on the
Train The Trainer (TTT) principle, GPs received training material and
were obligated to train their colleagues in the PHCC. Before and after
a training (symposium or TTT), all participants completed a ques-
tionnaire. After one and a half years, all PHCC in the province of
Yogyakarta were visited again to assess the long-term effects of the
training.
Results In total 703 GPs attended the symposia and trained 1349
staff members: 314 other GPs, 685 nurses and 350 midwives. After
the training, respondents’ average score regarding the knowledge of
NPC symptoms increased from 47 points (out of 100) to 74 (p <
0.001). There was no difference between symposium and TTT (p =
0.880). Two years after the training, the knowledge remained signifi-
cantly increased, at 59 points (p < 0.001). Overall, GPs scored better
compared to nurses (-18 points) and midwives (-20 points) on ques-
tions regarding symptoms. Similar results were found for knowledge
regarding NPC risk factors.
Discussion The initial results of this NPC awareness program provide
proof that the NPC awareness program is effective also in the long
term and therefore should continue. The effect of the improved
knowledge based on the stage at diagnoses of the NPC patients will
be scrutinized. In addition, patient-delay, doctors-delay and system-
delay causing the poor treatment outcome should be investigated in
more detail.
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The management of primary loco regionally advanced nasopharyn-
geal cancer (NPC) is fraught with technical challenges for safe and ef-
fective treatment due to its location in the sanctuary of the skull
base; great opportunity exists for tumor extension to regions of rela-
tive inaccessibility. The latter makes radiotherapy (RT) the most obvi-
ous choice for initial management compared to surgery, since the
disease is particularly radiosensitive.
The immediate proximity of critical structures (e.g. brain stem, spinal
cord and the optic apparatus) to target areas harboring disease in
the locally advanced setting represents the most important barriers
of delivery of curative RT with conventional technique. Ability to
avoid critical anatomy using precision techniques to plan, guide, and
deliver RT is paramount for this disease. Intensity-modulated radio-
therapy (IMRT) is currently the most usual precision RT approach. The
technical advances provided by IMRT enable conformation of tumori-
cidal doses delivered to concave shaped distributions, thereby pro-
viding, for the first time, the opportunity for safe delivery of high
doses to tumor while protecting normal tissues. The value of IMRT in
eliminating blindness and protecting salivary function as well as en-
hancing disease control has been demonstrated in randomized trials.
In parallel with IMRT, emerging imaging modalities (MRI and PET CT)
have also improved accuracy in target delineation. The implementa-
tion of volumetric image-guidance (IGRT) during radiotherapy has
further improved setup accuracy and provides an opportunity for
monitoring tumor volume and normal tissue changes over the
course of radiotherapy with the eventual promise of ‘real-time’ dose-
volume parameter adaption to anatomic structures when necessary.
Recently, particle therapy, such as intensity-modulated proton ther-
apy (IMPT), has emerged as an additional potentially attractive option
for this disease. However, the clinical benefit and cost-effectiveness
remain to be evaluated.
In parallel to advances in RT technique, progress has also been made
combining RT with systemic therapy. Since the proven benefit of
chemotherapy in enhancing RT loco regional effect and reducing risk
of distant metastasis was demonstrated in Inter group-0099, com-
bined RT with chemotherapy has become standard of care for loco-
regionally advanced NPC. However, controversies exist regarding the
sequence of chemotherapy, what agents to use, and which sub
group of patients benefit. Several clinical trials testing the benefit of
induction chemotherapy in addition to concurrent chemoradiother-
apy have been completed, and others are exploring a risk stratified
approach by selecting patients using post-radiotherapy EBV DNA ti-
ters for additional adjuvant chemotherapy. Network meta-analysis of
published clinical trial data may also provide additional evidence in
guiding optimal treatment for NPC.
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Nasopharyngeal carcinoma (NPC) is a rare disease in children with
distinct epidemiological and etiological features, histopathological
characteristic, and clinical presentation. NPC shows a bimodal age
distribution in non-endemic countries and the first peak is seen in
the second decade in addition to the second peak at more advanced
age. Juvenile NPC (JNPC) is one of the few malignancies in childhood
that emerge from the epithelium, and constitutes 1-5 % of all
pediatric cancers and 20-50 % of all primary nasopharyngeal malig-
nant tumors in children. The incidence of JNPC varies widely around
the world, and both genetic and environmental factors contribute to
the development of the disease. In the United States, only 3 % ofNPC occurs in patients younger than 19 years old according to SEER
data. JNPC almost always have the undifferentiated variant of the
disease, which is associated with advanced locoregional spread and
distant metastases. While the concomitant chemotherapy and radi-
ation, with or without adjuvant chemotherapy, is the current stand-
ard for adult patients with NPC, neoadjuvant chemotherapy with
radiotherapy has gained popularity parallel to other pediatric treat-
ment protocols in various solid tumours. The optimal radiotherapy
dose for disease control in JNPC has reportedly ranged from 50 to
70 Gy in the literature.
There are few prospective studies in the literature on the management
of JNPC. Currently, cisplatin-based induction chemotherapy followed by
high-dose radiotherapy is the treatment of choice. Although multi-
modality treatment has increased the 5-year survival to 70-90 %, late
morbidity is a major concern. Immune-modulation with interferon has
resulted with excellent outcome, and studies have been extended to
investigate the impact of immunotherapy on survival, in combination
with less toxic chemoradiotherapy. Integration of new chemotherapeu-
tic agents or modifiying their administration sequence when managing
JNPC’s is another way to improve results. A randomized phase II study
recently compared two versus three-drug regimen including docetaxel
in 72 JNPC. The results of this study did not show any benefit. It was
shown that intensity-modulated radiotherapy (IMRT) provides superior
target coverage and normal tissue sparing compared with conventional
radiotherapy in adult patients with NPC. However, compared with con-
ventional radiotherapy, a two-fold increase in integral dose has been
theoretically estimated with the use of IMRT due to the larger treat-
ment volumes. In the pediatric setting the risk could be significant due
to a higher inherent susceptibility of tissues. However, as the risk of sec-
ondary cancers related with IMRT estimated to be 2 % compared with
1 % for CRT, it seems logical to utilize IMRT in JNPC in order to decrease
the significant late effects. Although the optimal treatment modality for
JNPC has not been established, any potential reduction in radiation
field and doses is desirable due to the significant chronic morbidity
among long-term survivors.
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Epidemiological data on nasopharyngeal cancer (NPC) from Globo-
can 2012 showed that the total number of new cases in the world
amounted to 86,691 and number of deaths was 50,828. NPC has a
uniquely skewed geographic distribution, 81 % of new cases oc-
curred in Asia and 9 % in Africa. The top four countries (China,
Indonesia, Vietnam and India) accounted for 64 % of the global bur-
den. China has the largest number of new cases (n = 33,198), but in
terms of age-standardized incidence (ASI), China only ranked 19th be-
cause only the southern provinces have high incidence.
Radiotherapy (RT) is the primary treatment modality for NPC. We
conducted a study on the correlation of outcome with access to RT
to evaluate the fundamental requirement for RT facilities. Outcome
for each country was calculated by taking [1-(age-standardized mo-
dality/incidence)] as a proxy for 5-year relative survival (RS). Informa-
tion from the IAEA Directory of Radiotherapy Centres (DIRAC) was
extracted to calculate the number of RT equipment (linear acceler-
ator and/or Cobalt machine) and radiation oncologists per million
populations.
There were 112 countries with both outcome and RT data: the proxy
RS rate ranged widely from 0 to 83 % (median 50 %). Countries can
be categorized into poor (proxy RS < 50 %), median (proxy RS =
50 %), and good outcome group (proxy RS > 50 %). Among the 53
countries with poor outcome, the top 14 countries accounted for 75 %
of the global burden; their proxy RS rate ranged 22-41 %. Univariate lin-
ear regression showed a significant correlation between outcome and
the availability of RT: proxy RS increased at 3.4 % (p < 0.001) and 1.5 %
(p = 0.001) per unit increase in RT equipment and oncologist per mil-
lion, respectively. Comparison of median similarly showed statistically
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groups (p < 0.001). The median number of RT equipment per million
populations increased from 0.6 in the poor to 4.5 in the good outcome
group; the corresponding number of oncologists increased from 1.1 to
7.1. These findings will be useful in advocating cancer plan by govern-
ment, particularly those in developing countries.
Nasopharyngeal cancer is a highly treatable cancer. For patients
treated with good quality RT in experienced centers, 5-year disease-
specific survival exceeds 80 %. Concerted global efforts are urgently
needed to improve outcome in countries with poor outcome.
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Nasopharyngeal carcinoma (NPC) is a malignant tumor originated
from nasopharyngeal epithelial cells. The cancer is an Epstein–Barr
virus (EBV)-associated malignancy, with a remarkable racial and geo-
graphical distribution. Radiotherapy (RT) is the primary treatment;
while concurrent chemoradiotherapy with or without adjuvant
chemotherapy is the standard of care for advanced NPC. Although
the 5-year overall survival was up to 70 % in IMRT era, predicting me-
tastasis, recurrence, prognosis and therapeutic response of NPC re-
main a challenge. Therefore, discovery of biomarkers for predicting
treatment failure of NPC is of great importance for guiding NPC
treatment and improving patients’ prognosis. Thanks to the advance-
ments in proteomics and bioinformatics in the recent 20 years, a
great amount of biomarker that correlates NPC clinical parameters
were identified in DNA, RNA and protein level, respectively. All these
biomarkers were correlated with recurrence, distant metastasis, or
prognosis for NPC patients. Elevated levels of circulating cell-free Ep-
stein–Barr virus (EBV) DNA have been detected in plasma and serum
samples from nasopharyngeal cancer (NPC) patients by quantitative
real time PCR (qPCR) test. This qPCR test for circulating EBV DNA was
found to be useful in the clinical management of NPC patients.
Currently, plasma EBV DNA has gradually being adopted in clinical
applications and is considered to be the most attractive potential
biomarker to complement the TNM classification. Many other bio-
markers, such as serum C-reactive protein (hs-CRP), lactate dehydro-
genase (LDH), Cystatin A, and serum amyloid A (SAA), was associated
with recurrence and prognosis for NPC patients. However, now in-
corporating biomarker into new staging systems is still a challenge
for NPC patients. Even for plasma EBV DNA, test variation among la-
boratories should be addressed and the test of plasma EBV DNA
should be globally standardized before widely accepted by clinicians.
Therefore, to identify more reliable NPC biomarkers, new strategies
for biomarker screening need to be adopted, and clinical validation
and test of identified biomarkers in a large series of samples and
multicenter validation should be performed. A simple blood test for
evaluation of disease progress and therapeutic response individually
is expected to be a reality in the future.
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Southern China has recorded one of the highest rates of incidence of
NPC. The risk of NPC in China has long been associated with the HLApolymorphism. We have also detected protective as well as sus-
ceptible HLA factors in a southern Chinese NPC cohort from Guangxi.
In the present study we extended the genetic analysis to HLA inter-
action with KIR. The study cohort included three groups from
Guangxi: 1405 NPC cases, 1362 healthy individuals who are negative
for EBV/IgA/VCA (a precursor for NPC onset), and 1288 healthy indi-
viduals who are positive for EBV/IgA/VCA. Four-digit HLA typing was
performed using SBT. The KIR profiles (presence and absence of KIR
genes) were examined using SSP. HLA-A*11:01 was confirmed to be
the major projective allele (OR = 0.58, p < 0.0001). Another A*11 sub-
type A*11:02, on the other hand, showed no effect on NPC risk des-
pite the fact that the two A*11 subtypes differ from each other by a
single amino acid in position 19 which is outside the peptide binding
groove and therefore unlikely to influence peptide presentation.
However, this single replacement is known to influence A*11 inter-
action with KIR2DS4 with A*11:02 serving as a better ligand than
A*11:01. The analysis of compound HLA/KIR genotypes showed that
the presence or absence of KIR2DS4 did not change the protective
effect of A*11:01 but affected A*11:02 association with NPC develop-
ment and EBV/IgA/VCA conversion. When KIR2DS4 is absent A*11:02
showed an increased riskfor NPC onset (OR = 1.94, p < 0.005). It is es-
pecially true when the comparison was between NPC cases and the
EBV/IgA/VCA positive controls (OR = 5.3, p < 0.0001). A borderline sig-
nificance of the same compound genotype was also detected be-
tween the two control groups of EBV/IgA/VCA negative vs. positive
individuals (OR = 0.25, p = 0.002). In other words in the absence of
the KIR2DS4 gene individuals having A*11:02 are less likely to con-
vert to EBV/IgA/VCA positive but among those EBV/IgA/VCA positive
individuals the A*11:02+/KIR2DS4- genotype confers an increased risk
for NPC onset. These results indicate that HLA/KIR interaction might
indeed play a role in NPC pathogenesis.
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Introduction Epstein-Barr virus (EBV) is a necessary co-factor for the
development of nasopharyngeal carcinoma (NPC). Strong evidence
exists that antibody titers to latent and lytic-phase EBV proteins are
elevated years prior to NPC diagnosis, which has led to their ongoing
evaluation as high-risk NPC biomarkers. However, biomarkers that
can prospectively identify individuals at lower risk of developing NPC
have not been identified. Antibodies against proteins necessary for
EBV cell entry (i.e., antibodies that could neutralize virus infection)
represent a biologically plausible starting point to look for such low-
risk factors.
Aim We utilized the Taiwan Family Study (TFS) to evaluate the associ-
ation between risk of developing NPC and potentially neutralizing
antibodies against B-cell infection (EBV glycoprotein gp350 [gp350])
and epithelial cell infection (glycoprotein H/glycoprotein L [gH/gL]).
Methods The TFS is a prospective cohort of 2,557 individuals re-
cruited from 358 Taiwanese multiplex families (i.e., >2 family mem-
bers affected by NPC). Incident NPC cases were identified passively
(linkage to national tumor registry) and actively (clinical evaluation)
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matched (age, gender) individuals who remained disease-free during
follow-up (N = 50). Potentially neutralizing antibodies were measured
in baseline serum utilizing an immunoprecipitation assay. Baseline
serum was also tested for neutralizing potential against EBV infection
of B-cells and epithelial cells utilizing a rapid flow cytometry-based
neutralization assay. Finally, samples from prevalent NPC cases (N =
30 early stage; 10 late stage) were evaluated for gp350 and gH/gL
antibodies.
Results Average baseline gp350 antibody levels were significantly
lower (x = 24.10; p-value = 0.048) in those who developed NPC during
follow-up (median = 5 years) compared to individuals who remained
disease-free (x = 53.48). Similarly, serum from incident NPC cases neu-
tralized EBV infection of B-cells less potently (raw IC50 = 93.98) than
disease-free individuals (raw IC50 = 110.5), a statically significant differ-
ence when considering NPC diagnosed >1 year after baseline (p-value
= 0.026). Patterns differed according to the target cell type, with no ob-
served differences in the average baseline gH/gL antibody level or neu-
tralizing potential against EBV infection of epithelial cells according to
NPC status during follow-up. Elevated gp350 and gH/gL antibody levels
were detected at the time of NPC diagnosis (i.e., prevalent disease), re-
gardless of disease stage.
Conclusions Our results suggest that high-risk individuals with lower
gp350 antibody titers, which may neutralize EBV B-cell infection, are
more likely to develop incident NPC. If the pattern for this vaccine-
candidate antibody is replicated, it could provide an avenue for future
research into a previously-unidentified, low-risk NPC factor. The patterns
of this protective marker, however, differ between incidence and preva-
lent NPC cases, and the gp350 antibody may therefore not be useful
for NPC risk stratification in early detection screening programs.
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Advances in MR imaging in NPC
MRI is a versatile imaging modality providing both anatomical and
functional information in the same examination. MRI is one of the
most widely used modalities for imaging NPC and this lecture will
focus on some of the recent advances in MRI.
Advances in anatomical MRI
Detection of NPC
Nasopharyngeal MRI is a very sensitive technique for the detection
of NPC and it detects small NPCs buried in the pharyngeal recess or
beneath the mucosa that cannot be visualized by endoscopy. There-
fore, MRI has a role in the investigation of patients with suspected
NPC who have normal endoscopic findings, such as those patients
with elevated plasma EBV DNA. In these patients MRI can identify
the site of cancer for biopsy, while those patients without cancer can
be spared sampling biopsies. MRI also identifies a range of benign
hyperplastic changes in the nasopharynx, including adenoidal hyper-
plasia, which may cause false positive findings for NPC at endoscopy.
Advances in functional MRI
General
The head and neck is a technically challenging area in which to per-
form functional MRI. In addition there are variations in methods for
extracting data from the functional maps, and correlation of func-
tional data with treatment response is often based on only short-
term clinical follow-up. However, despite these drawbacks results,
functional MRI show promise in several areas of NPC evaluation. This
lecture will discuss very briefly some of these functional techniques
(DCE, MRS, CEST and ASL), but will focus mainly on diffusion weigh-
ted imaging (DWI) which shows the greatest potential for clinical use
in head and neck cancer.
DWI
NPC primary tumours and metastatic nodes show restriction of diffu-
sion which can be seen as high signal on the b-1000 DWI images and
low signal on the apparent diffusion coefficient (ADC) map. Currently
results from the small number of NPC research papers have shown apossible role for DWI in the following areas; (1) Tumour characterisation.
Differences have been shown between the ADC of NPC and the ADC of
other head and neck cancers, benign nodes, nasopharyngeal lymphoid
hyperplasia and skull base infection; (2) Pretreatment prediction of treat-
ment response. Sophisticated methods of ADC analysis using the distri-
bution of ADC values are promising for predicting long term treatment
response; (3) Intra-treatment monitoring. This is an area where DWI ap-
pears to have the greatest potential in cancer management. Over the
course of RT/CRT the ADC rises as tumour cells die. Results from both
squamous cell carcinoma and NPC suggest that a greater % rise in ADC
in the first few weeks of treatment indicates a more favourable re-
sponse. (4) Identification of post-treatment residual cancer. Residual can-
cers show restricted diffusion similar to that of the pretreatment
tumour, and the ADC values of residual cancers are lower than those of
post treatment inflammatory masses. Research from squamous cell car-
cinoma suggests that visual analysis of the DWI images + ADC maps
(residual cancer = high signal on b-1000 DWI + low signal on the ADC
map), may be superior to the measurement of ADC values.
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Introduction Epstein-Barr virus (EBV) has been suggested as the
strongest risk factor for nasopharyngeal carcinoma (NPC). We con-
ducted a multi-center case-control study in Taiwan to assess the in-
dependent effect of two EBV infection markers and interaction with
other environmental factors for newly developed NPC.
Aims This study aims to evaluate anti-EBV VCA IgA and anti-EBV EA-
EBNA1 IgA with other risk factors on risk of NPC development.
Methods A total of 1,656 histologically confirmed NPC cases, includ-
ing of 896 prospective cases and 760 retrospective cases, and 1,608
community controls were recruited between July 2010 and Decem-
ber 2014 in Taiwan. Six hundred and ninety-nine (699) NPC incidence
cases and 1,359 age-gender matched controls with adequate blood
samples and questionnaires were enrolled in the analysis. Informa-
tion on socio-demographic characteristics, cigarette smoking, betel
quid chewing, alcohol consumption, diet history, medical history,
and occupational history were collected by a standardized inter-
viewed questionnaire. Anti-EBV VCA IgA and anti-EBNA1 IgA were
tested in all blood samples. Unconditional logistic regression analysis
was used to estimate odds ratio (ORadj) with 95 % confidence inter-
val (CI) after adjusting for education years and ethnicity.
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increased NPC risk showing ORadj (95 % CI) of 57.0 (42.1-77.0, P <
0.001) for anti-EBV VCA IgA, and 91.3 (62.5-127.8, P < 0.001) for anti-
EBV EA-EBNA1 IgA. Compared to seronegative subjects, the ORadj
was 12.9 (8.3-20.0) for seropositivity of either anti-EBV VCA IgA or
anti-EBV EA-EBNA1 IgA, and 648.9 (377.5-999) for those who were
seropositive on both EBV seromarkers. In the stratification analysis,
the risk were higher for subjects who were seropositive on both EBV
seromarkers and without family history of NPC (ORadj = 719.6, 95 %
CI: 401.2-999 for subjects without family history vs. ORadj = 314.6,
95 % CI: 56.1-999 for subjects with family history). Compared to
never smokers, smokers with seropositive on both EBV seromarkers
had higher risk for NPC (ORadj = 922.5, 95 % CI: 370.8-999 for smokers
vs. ORadj = 534.2, 95 % CI: 268.3-999 for never smokers). Among sero-
positive subjects on both EBV seromarkers, the NPC risk was lower
for those with high intake of milk, deep-sea fish, dark vegetables,
and fresh fruit.
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Introduction Epstein-Barr virus (EBV) is a well-documented etiological
agent in the development of nasopharyngeal carcinoma (NPC). EBV
is known to infect the vast majority of adults worldwide (~95 %),
usually with lifelong persistence. However, only a small fraction of
EBV infected individuals are expected to develop NPC in their life-
time. Various co-factors have been postulated to be important deter-
minants of NPC.
Aim The study objective is to evaluate putative environmental expo-
sures and NPC.
Methods A total of 1,656 histologically confirmed NPC cases, com-
prised of 896 prospective cases and 760 retrospective cases, and
1,608 community controls were recruited between July 2010 and
December 2014. Controls were frequency matched to the cases on
age and gender. A standardized interviewed questionnaire was ad-
ministered by trained nurses to all subjects. Information on socio-
demographic characteristics, cigarette smoking, betel quid chewing,
alcohol consumption, diet history, medical history, and occupational
history were included. Unconditional logistic regression analysis was
used to estimate odds ratio (ORadj) with 95 % confidence interval (CI)
after adjusting for education years and ethnicity.Resultand discussion Compared to never smokers, current smokers
had an adjusted OR (ORadj) of 1.39 (95 % CI = 1.19-1.62) for NPC. Sub-
jects with a family history of NPC had an increased risk of NPC com-
pared to those without such a family history (ORadj = 3.77, 95 % CI =
2.84-5.02). Drinking milk (ORadj = 0.69, 95 % CI = 0.56-0.86 for the in-
take > = 2 times per week versus never), intake of dark vegetables
(ORadj = 0.45, 95 % CI = 0.33-0.61 for intake >1 times/week vs. <=4 times
per month), consumption of deep-sea fish (ORadj = 0.45, 95 % CI = 0.33-
0.61 for intake > =5 times per week vs. <=3 times per month), and in-
take of fresh fruit (ORadj = 0.49, 95 % CI = 0.39-0.60 for >1 time per week
vs <1 time per week) were all inversely associated with NPC risk.
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Introduction The genetic etiology of nasopharyngeal carcinoma
(NPC) remains unclear. We hypothesized that heritable NPC risk was
attributable to the cumulative effects of multiple common low-risk
variants. A multigenic pathway-based approach was used to system-
atically score the cumulative effects with SNPs in genes in DNA repair
pathways for NPC risk. Although the radiotherapy is very effective in
curing NPC patients with early- stage tumors, local failure and distant
metastasis remain major challenges for treatment and it is necessary
to identify prognostic biomarkers that predict poor clinical outcomes
of advanced-stage NPC patients.
Aims We aimed to identify genetic susceptibility genes involved in
NPC development and prognostic biomarkers for NPC patients.
Methods A case-control association study was performed with Mass
ARRAY genotyping of about 300 SNPs covering 161 genes/loci in
2,349 Hong Kong individuals including 1,177 NPC patients and 1,172
Red Cross individuals. Both single SNP and pathway based analysis
were performed for NPC risk. Patients were also stratified according
to their familial status for meaningful association analysis. For identi-
fication of the prognostic biomarkers of NPC, the clinical pathological
information of 1,177 NPC was collected for univariate and multivari-
ate statistical analysis for survival.
Results and discussions Single SNP association identified three
SNPs (rs401681, rs6774494, and rs3757318) corresponding to TERT/
CLPTM1L, MDS1-EVI1, and CCDC170 conferring modest protective
effects individually for NPC risk by the logistic regression analysis.
Stratification of NPC cases according to familial status identified
rs2380165 in BLM with an association with family history-positive
(FH+) NPC patients. Multiple SNP pathway-based analysis observed
cumulative effects for increasing numbers of unfavorable genotypes
in TERT- CLPTM1L and double-strand break repair (DSBR) conferred
elevated risk in FH+ and sporadic NPC patients. Our preliminary data
suggested a SNP in p53 with prognostic value for survival of NPC
patients. The prognostic role of p53 in NPC should be further vali-
dated in a larger cohort.
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Introduction Mass nasopharyngeal carcinoma (NPC) screening using
Epstein-Barr Virus (EBV) antibody as the primary screening test was
found to effect early diagnosis, but the long term effect of which has
not been ascertained.
Aim We conducted long term effects of NPC screening in a high inci-
dence area to assess the efficacy of NPC screening.
Method 16,695 residents of one town in Zhongshan City of southern
China aged 30 to 59 years in the screening arm and 33,390 residents
in two neighboring towns in the study arm matched for age, gender
and date of entry to study with each study subject at 2:1 ratio were
enrolled over 12 months since Aug 2009. A study subject initially
screened with medium EBV antibody levels and higher was invited
for retesting annually in the following 3 years and a subject initially
screened or retested and found to have high antibody levels was re-
ferred to otorhinolaryngologists for diagnostic workup for NPC.
Result and discussion Forty-one (n = 41) NPC cases were diagnosed
among study subjects and 45 among the control subjects over a median
follow-up of 52 months. Based on subjects referred for diagnostic workup,
the sensitivity of the screening triage was 94.9 % (0.827, 0.994), specificity
was 94.3 % (0.940, 0.946), the positive predictive value was 3.25 % (0.022,
0.043) and negative predictive value was 99.99 % (0.9997, 1.000). The cu-
mulative incidence of the participants was 0.246 %, 1.8 times that of the
control subjects. Most of the excessive diagnosis was probably because of
detection of future cases. This conferred on the population 92 % protec-
tion against NPC for at least 5 years. The proportion of cases diagnosed
with stage I & II disease was increased from 20 % to 78 % and the overall
survival rate was increased from 97.6 % to 82.2 %.
Conclusion We conclude that the NPC screening could confer 92 %
protection against NPC for 5 years and reduce death risk by 88.4 %
(0.05, 0.986).
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Introduction Nasopharyngeal carcinoma (NPC) is a malignant tumor
associated with host genetic predisposition and Epstein-Barr virus
(EBV) infection. Disease alerting and early prevention are key points
to reduce NPC burden.
Aims Our objective is to construct a prediction risk model of NPC
based on host genetic and EBV variation, screening those NPC sus-
ceptible population in a non-invasive and convenient way ultimately.
Methods SNPs and EBV variation were genotyped using the customed
Sequenome Mass ARRAY iPlex assay. The association and the inter-
action were observed under a logistic regression model. An optimal risk
prediction model was constructed through forward conditional method
to select the variables. Receiver operating characteristic (ROC) curve
analysis was used to illustrate the performance of the model.Results and discussion Firstly, we confirmed that the SNP geno-
typing result has no difference between the buffy coat and the saliva
in 116 paired samples. Thus we tested 8 single nucleotide poly-
morphisms (SNPs; rs2860580, rs2894207, rs28421666, rs9510787,
rs1572072, rs6774494, rs1412829 and rs31489) and the EBV subtype
(G > A mutation at locus 155391) simultaneously in saliva in a large
population-based case-control (1057 NPC cases and 1148 controls)
study, which replicated their associations with NPC except for
rs1572072. ROC curve analysis revealed the AUC of the NPC risk pre-
diction model inclusive of those 7 SNPs, EBV subtype and their inter-
actions was 0.74 (95 % CI 0.72-0.77) in the training cohort including
705 cases and 776 controls. The AUC was 0.72 (95 % CI 0.66-0.79) in
the independent validation cohort of 161 cases and 110 controls.
Taken together, this study confirms the strong contributions of gen-
etic and viral components to NPC susceptibility and develops a risk
prediction model with these factors using saliva samples. This model
can facilitate the screening of high-risk groups in a non-invasive and
convenient way and thus promote the prevention and earlier detec-
tion of NPC for those people.
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Aim The objective of this study was to examine patterns of care and
patient, tumor and treatment parameters in a sample of patients
with nasopharyngeal cancer (NPC) who were diagnosed and treated
by 14 Turkish radiotherapy centers in the year of 2014.
Methods Data of 122 patients primary NPC from 14 Turkish centers were
evaluated for patient's characteristics, staging characteristics, tumor pa-
rameters, use of plasma EBV DNA quantification, and trends in treatment.
Results Overall data of 122 patients were analyzed. There were 90 male
and 32 female patients (M/F ratio: 2.8/1). Age of the patients was
ranged between 11-81years old (median: 51 years old). There were 14
patients with age less than 30 years old. Histopathological diagnosis
was WHO I (12 patients), WHO II (24 patients), WHO III (81 patients),
and unclassified cancer (5 patients). Fourteen (11.4 %) out of 122 pa-
tients had cranial nerve involvement at initial diagnosis. PET staging
was used in 116 (95 %) and MRI staging was used in 108 (88.5 %) out
of 122 patients. Plasma EBV DNA analysis was available in 19 (15.5 %)
patients at diagnosis. Six (31.5 %) out of 19 patients were found to be
negative at initial diagnosis. Plasma EBV DNA level was ranged be-
tween 316-19.747.645 cp/ml (median: 43.683 cp/ml). Patient distribu-
tion according to T status was as follows: T1: 28, T2: 46, T3: 21, and T4:
27 patients. N status was as follows: N0: 18, N1: 37, N2: 51, N3a: 9, and
N3b: 7 patients. Stage distribution was as follows: Stage I: 4, Stage II: 24,
Stage III: 50, Stage IVA: 21, Stage IVB: 15 and Stage IVC: 8 patients.
Treatment parameters was as follows; radiotherapy alone: 9, concomi-
tant chemoradiotherapy (CCRT) alone: 64, CCRT + adjuvant chemother-
apy: 14, neoadjuvant chemotherapy and radiotherapy: 6, neoadjuvant
chemotherapy and CCRT: 28, and chemotherapy alone: 1 patients.
Radiotherapy was applied using 2D radiotherapy technique in 12 pa-
tients, with 3D conformal radiotherapy in 32 patients, with intensity
modulated radiotherapy in 77 patients (63.1 %).
BMC Proceedings 2016, Volume 10 Suppl 1 Page 10 of 24Conclusions This study was made as an initial step to achieve col-
laboration between Turkish radiotherapy centers to execute a multi-
centre study on NPC. The results have shown that PET-CT and MRI
staging is commonly available; however plasma quantification is
under-utilized among the centers. While a majority of patients were
treated with concomitant CCRT, adjuvant treatment was not pre-
ferred as it is in the endemic countries. IMRT is available in two third
of the patients. The data obtained in this study can be representative
of Turkish NPC patients.
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Introduction Intensity Modulated Radiation Therapy (IMRT) has be-
come standard technique for the treatment of nasopharyngeal can-
cer (NPC) in the recent years. It has achieved excellent locoregional
control with acceptable acute and late toxicities.
Aim To report the clinical outcome of NPC patients treated with IMRT
in our centre.
Methods This is a retrospective analysis of all patients with NPC
treated with curative intent in our Department of Radiation Oncology
in National Cancer Centre Singapore between 2000 and 2009. Clinical
outcome in terms of loco-regional control, disease free survival (DFS)
and overall survival (OS) were determined. 937 patients with Stage I-IVB
NPC were treated with definitive IMRT during this period. 68.2 % of pa-
tients presented with advanced stage; 35.6 % with Stage III and 33.6 %
with Stage IVA and IVB.
Results The median follow up time is 5.7 years. The 5 year local
control rate were as follows: T1: 92.6 %, T2: 88.8 %, T3: 87 %, T4:
77.5 %. The 5 year regional control rate were N0: 97.1 %,
N1:93.9 %, N2: 92.7 %, N3a: 89.2 %, N3b: 87.7 %. The 5 year
overall OS rate were Stage I: 98.8 %, Stage II: 86.2 %, Stage III:
83.4 %, Stage IVA: 69 %, Stage IVB 71 %. The 5 year DFS were
Stage I: 91.6 %, Stage II 76.1 %, Stage III 73.2 %, Stage IVA
59.2 %, Stage IVB 58 %. 265 (28.2 %) patients developed recur-
rences. Out of these, 91 patients (9.7 %) had locoregional recur-
rence only, 126 patients (13.5 %) had distant relapse only and 48
patients (5.1 %) had both loco regional and distant relapse.
Conclusion IMRT offers excellent long term disease control and sur-
vival in patients with NPC. Effective strategy is needed to optimize
distant control.
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BMC Proceedings 2016, 10(Suppl 1):O8Introduction Nasopharyngeal carcinoma (NPC) is a rare but aggres-
sive malignancy in children and adolescents.
Aim An international, randomized phase II trial was conducted to
compare induction chemotherapy with docetaxel plus cisplatin and
5-fluorouracil (TPF) with cisplatin and 5-fluorouracil (PF) in NPC pa-
tients under the age of 21.
Methods Patients with stage IIB-IV NPC were randomly assigned, in a
2:1 ratio, to receive TPF or PF three-weekly for 3 cycles, followed by
chemoradiotherapy. The primary endpoint was the complete re-
sponse rate achieved with TPF or PF. Docetaxel pharmacokinetics
were also evaluated.
Results and discussion Seventy-five patients (median 16 years old)
were randomized, with 50 assigned to the TPF group and 25 to
the PF group. Overall response was assessed after induction treat-
ment: 1 patient in the TPF group and none in the PF group had a
complete response. Partial response was achieved in 76.0 % and
80.0 % in the TPF and PF group, respectively. The overall safety
profile was consistent with findings in adults. The estimated 3-year
overall survival rate was 78.0 % for the PF group and 85.7 % for
the TPF group (median follow-up 3.3 years). Mean docetaxel area
under the curve was 3.41 μg.h/mL, compared to 3.51 μg.h/mL seen in
adult patients.
Conclusion This study demonstrated the feasibility of prospective
randomized protocols, even for such rare tumors as pediatric NPC.
Overall, there were no differences between the 2 treatment arms
in terms of efficacy and toxicity. The pharmacokinetics of doce-
taxel in pediatric patients at 75 mg/m2 were similar to those ob-
served in adults.
(This study was supported by Sanofi).O9
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Introduction The M1 stage of TNM classification in nasopharyn-
geal carcinoma (NPC) does not discriminate patients based on
metastatic site and number of metastatic lesions. The role of
metastatic status in predicting survival has not been analyzed in
the local setting.
Aim This study aimed to determine the prognostic impact of meta-
static status of NPC patients.
Methods Data of 81 metastatic NPC patients diagnosed between
January 2007 and December 2011 were retrospectively reviewed.
Diagnosis of metastasis was based on imaging results. Patients
were grouped according to various prognostic variables, including
age (<50 versus ≥ 50 years), sex, histology grading, T and N classi-
fication, the time order of metastasis (synchronous versus
metachronous), and number of metastatic sites (single versus
multiple). Rates of overall survival (OS) were calculated using the
Kaplan-Meier method. The log rank test was performed to
analyze the difference between survival curves. Cox regression
was used to calculate the hazard ratio (HR) and 95 % confidence
interval (CI).
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from 12.4-36.4 months). The 1 year-, 2 year-, and 3 year-survival rate
were 64.4 %, 49.5 %, and 39.0 %, respectively. Involved single
metastatic sites included the bone (39, 48.1 %), lung (18, 22 %),
liver (11, 13.6 %) and brain (1, 1.2 %), whereas the involvement
of multiple organs occurred in 12 (14.8 %) patients. In univariate
analysis, patients with lung-only metastasis had favourable
survival compared with other single- (HR = 0.698, 95 % CI 0.236-
2.065) and multiple-distant metastases (HR = 0.195; 95 % CI0.653-
0.058). T4 and N1-N3 were insignificant negative predictors for
survival (HR = 1.937, 95 % CI 0.887-4.229 and HR = 3.712, 95 % CI
0.502-27.472, respectively). Interestingly, cases with metachronous
lesion had worse survival than those with synchronous disease
(HR = 2.312, 95 % CI 1.090-4.900). However, when tested in multi-
variate analysis, metastatic site was the only significant independ-
ent prognostic factor for patients’ survival (95 % CI 0.912-0.449),
while metastatic time lost its prognostic influence (95 % CI 0.224-
1.018).
Conclusion In the local patient cohort, metastatic site had a prognos-
tic impact on patients’ survival.O10
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Introduction EBV is a DNA tumor virus etiologically associated with
1-2 % of all human cancers including Burkitt's lymphoma (BL), Hodg-
kin's lymphoma and nasopharyngeal carcinoma (NPC). Currently, no
pharmaceutical-based therapies exist that selectively target EBV la-
tent infection. EBV latent infection depends on the continuous ex-
pression of Epstein-Barr Nuclear Antigen 1 (EBNA1), a multifunctional
dimeric protein critical for viral replication, genome maintenance,
and viral gene expression.
Aim The aim of this program is to advance the development of a
New Chemical Entity (NCE) for latent infection of Epstein-Barr Virus
(EBV) to treat NPC.
Methods We have used structure-based drug design and
medicinal chemistry methods to develop a small molecule
lead series that selectively inhibits the DNA-binding activity of
EBNA1.
Results and discussion The lead series inhibits the EBNA1 func-
tion with nanomolar potency in biochemical assays and low mi-
cro molecular activity in several cell-based assays, including
ChIP assays. We demonstrate that these inhibitors provide pro-
tection in xenograft models of EBV-driven tumor growth of NPC
cell lines. Furthermore, EBER-ISH experiments confirm in vivo tar-
get engagement by the elimination of EBV in treated tumor tis-
sue. The inhibitors are selective, showing no activity against
KSHV LANA in the biochemical assay, no cell-killing activity of
EBV-negative cells, and no tumor growth inhibition in an EBV-
negative xenograft experiments. The lead series meet or exceed
industry-accepted criteria for drug suitability, safety and toxicology in-
cluding physicochemical properties, metabolic stability, selectivity in
broad-based screens and bioavailability, and the absence of in vivo li-
abilities, including genotoxicity and 14-day toxicity studies. These data
establish proof-of-concept for targeting EBNA1—a protein previously
thought to be undruggable.O11
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Introduction Cancer stem-like cells (CSCs) are sub-population of
treatment resistant cells and have the tumor initiating ability. The
presence of CSCs is suggested to be associated with tumor relapse
and metastasis after conventional treatments. The Wnt signaling
pathway involved in CSC maintenance is known to be aberrantly ac-
tivated in most of the NPC patients. ICG-001 is a Wnt modulator that
can specifically block the interaction between coactivator CBP and β-
catenin to inhibit the transcription of genes associated with the
maintenance of stemness properties.
Aim We hypothesized that ICG-001 can reduce NPC cells with stem-
like phenotypes and enhances the efficacy of cisplatin on NPC.
Methods We employed the 3-D tumor sphere formation assay as
a functional assay to enrich the CSC-like cellsto study the effect
of ICG-001 on the CSC-like population. Also, we performed
a combination study of ICG-001 with the conventional drug
cisplatin to evaluate the in vitro and in vivo efficacy of the treat-
ment on NPC.
Results and discussion Using the EBV-positive C666 cell model,
ICG-001 was found to significantly reduce the growth of tumor
spheres and reduce the spheroid cells with SOX2hi/CD44hi CSC-
like phenotype. The reduced SOX2 expression was found to be
associated with restored expression of the tumor suppressive
microRNA-145 (miR-145). Ectopic expression of miR-145 effect-
ively repressed SOX2 expression and inhibited tumor sphere for-
mation. Furthermore, the combination of ICG-001 with cisplatin
demonstrated a better tumor suppressive effect than the cis-
platin treatment alone on the EBV-positive NPC xenograft
models. These results suggest that therapeutic targeting of the
Wnt signaling pathway by ICG-001 may reduce the CSC-like
population in NPC and enhance the tumor suppressive effect
of NPC to cisplatin. Future clinical investigations of ICG-001 (PRI-
724, the second generation of ICG-001 for clinical study) com-
bined with cisplatin may benefit NPC patients from a better
treatment outcome.O12
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Introduction One of the major clinic-translational challenges in naso-
pharyngeal carcinoma (NPC) is the pre-identification of patients who
will develop distant metastasis in order to develop a personalized
treatment approach.
Aim Using a training: validation design, we wished to identify a
micro-RNA (miRNA) signature which can identify risk of developing
distant metastasis in NPC patients.
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formalin-fixed paraffin-embedded (FFPE) biopsy samples using the
Nanostring nCounter Human miRNA Platform, which measured the
expression of 732 miRNAs, including 654 human and 78 viral, includ-
ing EBV miRNAs.
Results and discussion From the 125 samples in the training set, the
expression levels of 4-miRNAs were identified to be significant prog-
nosticators for distant metastasis: miR-154, miR-449b, miR-140, and
miR-34c, with a HR of 8.25 (p < 0.001). This was validated in the
second independent NPC cohort of 121 samples, with a HR of 3.2
(p = 0.010), and determined to be independently prognostic, in
addition to clinical nodal status (Bruce et al; Oncotarget 6:4537;
2015). Pathway analysis indicated that cell cycle regulation ap-
peared to be targeted by these 4-miRNAs, which was corroborated
to be an important pathway based on results of a recent whole
exome sequencing study (Lin et al; Nat Genet 46:866, 2014). Preliminary
data generated using NP69 (normal nasopharyngeal epithelial) cell lines
indicated that transfection using anti-miR-34c plus pre-miR-449b
suppressed cell proliferation, and potential mRNA targets including
CDKN1A and p53 were identified, as well as bcl-2, DNMT1, NOTCH1,
HMGA2, and MMP13.
Conclusion Further interrogation of these 4-miRNAs could provide
important biological insights that could facilitate the discovery
and development of novel molecularly-targeted therapies to im-
prove outcome for future NPC patients by preventing distant
metastasis.O13
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Introduction Nasopharyngeal carcinomas (NPC) are endemic in
Asia and Mediterranean areas, where they are associated with
Epstein Barr Virus (EBV) infection. They are diagnosed at an ad-
vanced stage in 75-90 % of cases owing to their deep ana-
tomic location. Despite better response than in other head and
neck cancers, the five-year survival is about 75 %. However,
the outcomes for patients with metastatic or locally recurrent
EBV-positive NPC remain poor.
Aim To develop more effective therapies for NPC, adoptive lympho-
cyte therapy with EBV-specific T-cells has been proposed as a very
promising immunotherapeutic approach to treat EBV-associated
diseases.
Methods In this study, we performed a novel procedure to
rapidly generate multivirus-specific cytotoxic lymphocytes for
treatment of viral infection proposed recently by Gerdemann
et al. 2012. A specific preparation of polyclonal specific anti-
viral T-CD4 and T-CD8 population can be achieved by a single
round of stimulation with viral peptides and growth in the
presence of prosurvival cytokines.
Results and discussion In the present study we show that this ap-
proach is suitable to rapidly generate batches of specific EBV la-
tency II T-cell from NPC, which importantly are devoid of regulatory
T-cell.O14
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Introduction Little is known about patients’ experiences of Amifos-
tine radiotherapy treatment (ART) for nasopharyngeal carcinoma
(NPC) or how it impacts on their quality of life (QoL).
Aims The study examined patients’ perspectives on ART, in order to
explore their understanding and experience on medium to long-
term effects QoL. Taking a patient-centered approach enabled an
exploration of perceived limitations of the treatment, and the op-
portunities for improvement in relation to patients’ psychological
wellbeing.
Methods Six semi-structured interviews were conducted using ques-
tions inspired by EORTC QLQ-C30 questionnaire and QLQ-H&N35
module for examining QoL in head and neck cancer patients. The
participants selected had undergone ART at the Radiotherapy De-
partment of Cancer Hospital of Sun Yat-sen University and were
cancer-free, i.e. successfully completed treatment at least 12 months
previously with no signs of recurrence. Thematic analysis was used
to analyse the interview transcripts.
Results and discussion The study found that ART had minimal nega-
tive impact upon patients’ QoL in long-term. NPC survivors suffered
from mild long-term side effects (dry mouth), with only short-term
severe side effects (headaches, ragged oral cavity, and tiredness).
Since treatment, patients exhibited a sensitive self-awareness that
allowed them to maintain a positive attitude towards the treatment.
They were highly attached to the senior consultant and sought op-
portunities to meet him, which helped patients to maintain a positive
attitude. However, due to lack of understanding on their treatment,
several patients expressed feelings of anxiety that triggered them to
seek information online, which only resulted in further anxiety. Partic-
ipants also reported strong fears of relapse, and doubted the results
provided by the hospital. Despite coming into contact with several
other healthcare professionals, patients expressed a need to seek re-
assurance from the senior doctor. Thus, this study suggests a need
for more comprehensive management of information shared with
patients regarding their treatment, and structured psychological sup-
port at all stages of the treatment. Furthermore, better use of the
wider clinical team could be used following work with patients to
raise awareness of their roles.O15
Analysis of mitochondrial DNA mutation in latent membrane
protein-1 positive nasopharyngeal carcinoma
Pudji Rahaju (pudjitht@gmail.com; pudji_tht@yahoo.co.id)
Faculty of Medicine Brawijaya University, Malang, Indonesia
BMC Proceedings 2016, 10(Suppl 1):O15
Introduction Nasopharyngeal carcinoma (NPC) is the most malignant
disease in the head and neck areas. Epstein-Barr Virus (EBV) plays
an important role in NPC carcinogenesis. Mitochondria is important
in intrinsic apoptotic signaling and ATP energy forming through
oxidation-phosphorylation.
Aims We have explored the influences of mitochondrial DNA (mtDNA)
mutation particularly cytochrome-oxidase I, II, III, ATP-synthase 6 and 8
genes from nasopharyngeal tissue biopsy of NPC patient (WHO III,
LMP-1 positive) in apoptotic signaling and ATP energy forming.
Methods We used nasopharyngeal tissue biopsy and determined
mutation of mitochondrial DNA CO I, II, III, ATPase 6 and 8 by
electrophorese, PCR and sequencing. We checked the distribu-
tion of protein cytosol cytochrome-c, caspase 9, 3 and ATP syn-
thase by immunohistochemistry. We analyzed the data using
Chi-square test and ANOVA.
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was a significant association between the type of mtDNA mutation
and the distribution of those proteins. By ANOVA analysis it was
found that there was significant association between the type of
genes and the number of mutation between CO III gene as com-
pared to CO I and CO II genes, ATPase 8 with ATPase 6, substitution
with deletion and insertion. It was concluded that all EBV LMP-1
positive-NPC patients who experienced mtDNA mutation of coding
region and types of mutation in those genes had a strong associ-
ation toward the distribution of protein cytosol that induce apoptosis
and ATP energy forming.O16
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Introduction Adherence to treatment regimens offers both a
better survival rate and lower recurrence in nasopharyngeal can-
cer (NPC) patients. Various factors influencing the adherence to
long term therapy include socio economic and medical factors.
Understanding those factors is essential to improve the patients’
outcome.
Aims This study aims to define factors influencing adherence of NPC
patients to their treatment regimens and the correlations between
those factors and clinical outcomes.
Methods A retrospective cohort study was conducted in Dr. Sardjito
Hospital based on medical record from 2007-2011. Factors examined
were socio-demography, baseline characteristics, and survival. Adher-
ence was defined as completion of the entire course of therapy and
clinical follow-up. Data were described and analyzed with Kruskall-
Wallis analysis. Kaplan-Maier survival analysis was done to observe its
clinical outcome.
Result and discussion From 274 NPC cases, we found 184 (67.2 %)
patients were adherent. Most of non-adherent patients (32.8 %)
were due to lost to follow up (73.3 %), financial problems (9.9 %),
adverse event (7.8 %), patient refusal (4.4 %), death (4.4 %), and
empty stock of drugs (1.1 %). Patient adherence showed significant
correlations with baseline staging (p = 0.0001), with stage III-IVA
showed better adherence compared with those in stage IVB-IVC.
Patients with nasal blockage (p = 0.050), epistaxis (p = 0.320), ring-
ing ear (p = 0.570) had been more adherent compared with other
complaints. The overall survival (OS) and clinical response were bet-
ter in adherent than non-adherent patients (p = 0.0001) with me-
dian OS of 1.5 and 0.53 years, respectively. Moreover, adherent
patients had more significant result in one, two, and three-year OS
(p = 0.0001; p = 0.0001; p = 0.040). However, it declined in the fol-
lowing four and five year OS (p = 0.993; p = 0.174). The adherence
showed poor correlations with sex (p = 0.534), first visit age (p =
0.916), education status (p = 0.947), occupation (p = 0.752), covering
insurance (p = 0.825), neck mass complain (p = 0.347), faster diagno-
sis (p = 0.592), histopathology type (p = 0.278), and free-disease sur-
vival (p = 0.341). Further attention should be given to the factors
influencing the adherence to treatment to finally improve patients
outcome.O17
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Introduction Chronic rhinosinusitis (CRS) has been recognised as a
risk factor for nasopharyngeal carcinoma (NPC). CRS can be triggered
by gastroesophageal reflux (GER) that may reach the nasopharynx.
Bile acid (BA), the main component of refluxate, is a potential car-
cinogen. BA-induced apoptosis has been implicated in various malig-
nancies. Chromosomal breakage is an early event in both apoptosis
and chromosomal rearrangement. Matrix Attachment Region/Scaffold
Attachment Region (MAR/SAR) appears to be a preferential site of
chromosomal breakage. We hypothesised that BA-induced apoptosis
may cause chromosomal breaks at MAR/SAR leading to NPC chromo-
somal rearrangements.
Aims To identify BA-induced chromosomal breaks within AF9 (9p22)
SAR and non-SAR regions.
Methods MAR/SAR sites in the AF9 gene were predicted by MARS-
CAN. NP69 cells were treated with BA at neutral and acidic pH. Flow
cytometric analyses of phosphatidylserine (PS) externalization and
mitochondrial membrane potential (MMP) disruption were performed.
Inverse-PCR (IPCR) was employed to detect cleavages in SAR and non-
SAR regions. IPCR bands were sequenced.
Result and discussion Treatment of NP69 cells with BA at neutral
and acidic pH resulted in increased apoptosis and increased cleavage
frequencies of the SAR region. No significant difference was detected
in non-SAR cleavage frequency between untreated cells and cells
treated with BA at neutral or acidic pH. A few breakpoints detected
in the SAR region were mapped within the AF9 region that was
previously reported to be involved in the formation of MLL (Mixed
Lineage Leukaemia)-AF9 fusion gene in acute lymphoblastic leukae-
mia (ALL) patient. Our findings suggested that BA-induced apoptosis
could be one of the mechanisms underlying NPC chromosomal rear-
rangements. MAR/SAR may play an important role in chromosomal
breaks mediated by BA-induced apoptosis.
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Introduction Recurrences remain frequent in nasopharyngeal carcin-
oma (NPC) patients, despite having received complete therapy. Re-
cent studies have proven that recurrences were caused by NPC
cancer stem cells that were resistant to radiotherapy. The mechanism
of resistance in cancer stem cells to radiotherapy was assumed to be
due to the blocking of apoptosis and/or proliferation induction. The
blocking of apoptosis was caused by the decreased of p53 (wild
type) expression.
Aim To describe the mechanism of NPC stem cells resistance to
radiotherapy based on p53 (wild type) profiles.
Methods We used a experimental study with pre- and post-test con-
trol group design. The cultured NPC stem cells were divided into two
BMC Proceedings 2016, Volume 10 Suppl 1 Page 14 of 24groups, each with 16 samples. The treatment group had 1.5Gy dose
of radiotherapy exposure with Linac device, then incubated for
24 hours. Both groups were analyzed for p53 (wild type) before and
after treatment. The analysis were done by flow cytometry.
Result The p53 (wild type) expression between the treatment and
control group showed no significant difference (p = 0.576).
Conclusion No changes of p53 (wild type) on NPC stem cell that re-
sistant to radiotherapy.
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Introduction Nasopharyngeal carcinoma (NPC) is a cancer that oc-
curs due to tumor malignancies in nasopharyngeal epithelial cells.
This cancer is related to Epstein-Barr Virus (EBV) infection, as almost
all NPC tumor cells contain EBV, and most people with NPC showed
evidence of infection by this virus in their blood.
Aims The aim of the research is to determine the length of the
process of development from normal cells into invansive carcinoma
cells. This research also can describe the comparison of the amount
of normal cells and invansive carcinoma cells at a certain time.
Methods Mathematical modeling on the development of normal
cells to invasive carcinoma cells. The processes in celluler level were
divided into six sub-populations consisting of normal, lesion, low dys-
plastic, infection, high dysplastic, invansive carcinoma cells and one
lytic EBV sub-population. All sub-populations are modeled in the sys-
tem of differential equations.
Result and discussion Within a mathematical model, we obtained
three conditions of cells where the virus exists, i.e. the lesions which
occurred from non-infected cells, the cells which are infected but did
not develop into invasive carcinoma, and the infected cells with inva-
sive carcinoma.
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Introduction. Nasopharyngeal carcinoma (NPC) is a common malig-
nancy of the head and neck in South-East Asia, including Indonesia.
MicroRNA-21 (miR-21) has been considered as the most active
miRNA and play important role in several cancers, including NPC.
Aim. In this research, we analyzed the expression of miR-21 on NPC
patients and compared it to healthy people. We also determined its
correlation to the stage of NPC.
Methods. A total of 63 samples from 53 NPC patients and 10 healthy
controls were used in this study. In the patient group, there were
seven individuals with early stage and 46 with advanced stage. Total
RNA were isolated from plasma, cDNA was synthesized, and quanti-
fied by means of qPCR.
Result and discussion. Our results showed that miR-21 expressions
in patients’ samples were significantly different from those of healthy
controls (p = 0.0013). The Livak’s model showed that the expression
of miR-21 on NPC plasma was elevated to 20 times than healthycontrol. The expression of miR-21 on patients with advanced stage
was up to 10 times than those with early stage.
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The endocrine fibroblast growth factor 19 (FGF19) subfamily contains
three members - FGF19, FGF21 and FGF23, critically implicated in the
pathogenesis of multiple malignancies. Here we report that, although
with limited expression in few normal adult tissue types, FGF19 is
overexpressed in multiple carcinomas especially nasopharyngeal car-
cinoma (NPC) and digestive tract cancer tissues. Overexpression of
FGF19 promoted tumor cell proliferation and colony formation, and
also enhanced tumor cell migration and invasion. Knockdown of en-
dogenous FGF19 suppressed the viability, clonogenicity, migration
and invasion abilities of tumor cells. FGF19 activated ERK, AKT and β-
catenin signaling through upregulating the phosphorylation of AKT,
β-catenin and ERK1/2. We also found that knock-down of FGF19
inhibited tumor cell epithelial-mesenchymal transition (EMT), accom-
panied by increased expression of epithelial marker E-cadherin and
decreased expression of mesenchymal markers N-cadherin, SLUG
and fibronectin. FGF19 regulated F-actin rearrangement through pro-
moting RhoA phosphorylation, further modulating the EMT process.
Moreover, FGF19 could induce tumor cell resistance to doxorubicin
through ERK signaling pathway. Application of an anti-FGF19 anti-
body successfully suppressed tumor cell migration and invasion.
Thus, FGF19 exerts oncogenic functions in NPC and other tumor
cells, and could serve as a therapeutic target.
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Introduction We have demonstrated that administration of autolo-
gous EBV-specific T cells (EBV-T cells) to patients with NPC is feasible,
safe and associated with anti tumor responses especially for loco-
regional disease. However, the anti-NPC activity of EBV-T cell lines
generated by our standard method is limited by several factors,
including: i) low frequency of T-cells targeting EBV antigens se-
lectively expressed in NPC (LMP1, LMP2, EBNA1 and BARF1), and
ii) sensitivity of infused T cells to the immune suppressive tumor
microenvironment.
Aim The goal of this study was to generate a clinical grade NPC-
specific T-cell product that recognizes at least 2 EBV antigens
expressed in NPC and that is resistant to TGFβ, a common immune
evasion strategy used by tumors including NPC.
Methods We used good manufacturing practice (GMP) grade pep-
mixes, cytokines, and artificial antigen presenting cells to generate
NPC-specific T-cell lines. These T cells were genetically modified to
BMC Proceedings 2016, Volume 10 Suppl 1 Page 15 of 24express a dominant negative TGFβ-receptor (TGFβ-DNR) to render
them resistant to TGFβ.
Results and discussion We successfully generated NPC-specific T-
cells from 7 NPC patients. As compared to our standard method,
manufacturing time was reduced from 3 months to less than 4 weeks.
As judged by IFNγ elispot assays, generated T-cell lines recognized at
least 2 NPC-associated EBV antigens, and had 1-2 logs higher fre-
quency of T cells specific for LMP1, LMP2, EBNA1 and/or BARF1 in
comparison to T cell lines generated by our standard method. Trans-
duction of NPC-specific T cells with a GMP-grade retro virus encoding
TGFβ-DNR resulted in transgene expression in 50-80 % of T cells de-
tected by FACS analysis. A clinical study (NCT02065362) to evaluate
the safety and antitumor activity of our ‘next generation’ NPC-
specific T cells opened for patient accrual in January 2015. TGF-β re-
sistant, NPC-specific T cells may present a promising alternative to
currently available therapies for NPC.
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Introduction Recent research demonstrates that intracellular Hsp70
has a crucial role in the growth, invasion, and metastasis of NPC.
Aims This study was conducted to analyze intracellular Hsp70 protein
expression of NPC samples and see the correlation between the ex-
pression and the NPC stage.
Methods The study was cross sectionally designed. Formalin-fixed
paraffin-embedded biopsy specimens were obtained from 20 cases.
All patients were histopathologically confirmed as NPC and clinically
determined as stage I, II, III, or IV. The expression of intracellular
Hsp70 was detected by immunohistochemistry using anti human
Hsp70 antibodi (Santa Cruz Biotechnology, California, USA). Staining
assessment was performed using Remmele method. Statistical ana-
lysis was done using the Spearman’s test. Statistical significance was
defined as p < 0.05.
Results and discussion The negative staining of intracellular Hsp70
expression was found in 15 % of the samples which consisted of 1
patient of stage I, II and III, and no patient of stage IV. Mild positive
was found in 25 % of the samples which consisted of no patient of
stage I and III, 2 patients of stage II, and 3 patients of stage IV. Mod-
erate positive was found in 25 % of the samples which consisted of
no patient of stage I and II, 1 patient of stage III, and 9 patients of
stage IV. Strong positive was found in 10 % of the samples which
consisted of no patient of stage I, II, III, and 2 patients of stage IV.
Spearman’s test showed a correlation coefficient of 0.671 (p = 0.001),
suggesting a correlation between increasing of the intracellular
Hsp70 expression and NPC clinical stage.
O24
Epstein-Barr virus serological profiles of nasopharyngeal
carcinoma - A tribute to Werner Henle
Mingfang Ji, YaruiXu, Weimin Cheng, ShengxiangGe, Fugui Li, Ng MH
Cancer Research Institute of Zhongshan City, Zhongshan People’s
Hospital, Zhongshan City, Guangdong Province, PRC
Correspondence: Mingfang Ji (jmftbh@sina.com) – Cancer Research
Institute of Zhongshan City, Zhongshan People’s Hospital, Zhongshan
City, Guangdong Province, PRC
BMC Proceedings 2016, 10(Suppl 1):O24
Introduction In 1976, Werner Henle and colleagues reported that
serum levels of Epstein-Barr Virus (EBV) antibody of immunoglobulin
subtype A (IgA) were generally elevated among nasopharyngealcarcinoma (NPC) patients. It was believed that this “outstanding”
serological feature might be attributed at least partly to the life cycle
of the tumor-associated virus.
Aim To test this hypothesis and to explore the scope for application
of this feature in management of NPC.
Methods We developed seven EBV specific ELISA’s using purified re-
combinant proteins of the following EBV antigens: EBNA1, EBNA2 as-
sociating with EBV latency; the non-structural antigens, zta, TK, EA-R
EA-D comprising the early antigen complex (EA); and the structural
antigen, VCAp18, associating with replication cycle of the virus.
Results and discussion We determined levels of the corresponding
IgA antibodies of 347 donors and 182 newly NPC patients. All the pa-
tients’ sera were obtained before treatment, 64 were occult cases
identified through NPC screening program and apparently not aware
of by the patients and 118 were symptomatic cases presenting at
outpatients’ clinics. We showed that the levels of all the antibodies
were significantly higher for NPC patients than the donors, except
EBNA2 antibody. The levels of EBNA1 antibody were similar for the
occult cases and the symptomatic cases and remained relatively con-
stant as the disease progressed. In contrast, the levels of the EA anti-
bodies were higher for the symptomatic cases than the occult cases.
The levels also increased as disease advanced, and with tumor bulk
and involvement of loco-regional lymph nodes. But, with the pos-
sible exception of TK, the levels of the EA antibodies did not appear
to also increase with metastasis. The levels of p18 antibody of the
NPC patients were higher than the donors, but did not consistently
change with disease progression.
Conclusion These findings suggested that the outstanding sero-
logical feature originally observed by Henle and colleagues is attributed
to the EBV associating with loco-regional tumors. The serological pro-
files are compatible with a virus life cycle characterized by latency II
attended by occasional reactivation of the latent virus which usually
aborts before production of virus.
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Introduction Distant relapse is a major cause of mortality among pa-
tients with nasopharyngeal cancer (NPC). This preclinical study ex-
plores the feasibility of targeting the apoptotic pathway in NPC.
Aims We aim to investigate the enhancement of NPC cells apoptosis
following combination therapy with poly I:C and YM-155, as well as
determined the degree of cisplatin induced cytotoxicity of pre-
treated NPC cells with YM-155 and poly I:C.
Methods TLR3 and survivin expression were investigated on NPC cell
lines (HONE1 and C-666) before and after treatment with poly I:C
and YM-155 by using flow cytometry. Apoptotic cell death was evalu-
ated using Annexin V and propidium iodide assay. Next, cytotoxic ef-
fect of cisplatin was measured using the resazurin assays (PrestoBlue,
Invitrogen). The degree of cisplatin induced cytotoxicity was analyzed
following pre-treatment of NPC cells with poly I:C and YM-155. Mann
Whitney test was used to evaluate the statistical significance be-
tween groups.
Results and discussion Both HONE1 and C-666 cells expressed TLR3
and survivin on flow cytometry. Poly I:C (0.1-100 μg/ml) treated cells
do not affect the expression of TLR3 but induce modest apoptosis
(10-15 %) of NPC cells. YM-155 significantly induced apoptosis in a
dose-dependent manner with an IC50 value of 50nM. Combination
therapy with poly I:C and YM-155 enhanced NPC cells apoptosis syn-
ergistically compared to any type drug alone (p < 0.050). Cytotoxic ef-
fect of cisplatin was significantly enhanced following prê-treatment
with YM-155 compared to untreated cells (p < 0.001). The addition of
poly I:C pre-treatment to NPC cells demonstrated enhancement of
cisplatin induced cytotoxicity only at high concentration of poly I:C
(100 μg/ml; p < 0.030).
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tosis of NPC cells. However, YM-155 was more effective in sensitizing
NPC cells to cisplatin induced cytotoxicity compared to poly I:C. Tar-
geting the apoptosis pathway in combination with cisplatin in NPC
merits further study.
O26
The resistance mechanism of nasopharyngeal cancer stem cells to
cisplatin through expression of CD44, Hsp70, p53 (wild type),
Oct-4, and ß-catenin encoded-genes
Achmad C Romdhoni2, Fedik A Rantam2,3, Widodo Ario Kentjono1
1Department of Otorhinolaryngology Head and Neck Surgery, Faculty of
Medicine, Universitas Airlangga, Surabaya, Indonesia; 2Stem Cell
Laboratory, Institute of Tropical Disease, Universitas Airlangga, Surabaya,
Indonesia; 3Department of Virology, Faculty of Veterinary, Universitas
Airlangga, Surabaya, Indonesia
Correspondence: Achmad C Romdhoni (romdhoni_ent@yahoo.com) –
Department of Otorhinolaryngology Head and Neck Surgery, Faculty of
Medicine, Universitas Airlangga, Surabaya, Indonesia
BMC Proceedings 2016, 10(Suppl 1):O26
Introduction Chemotherapy does not always give a good response
in patients with nasopharyngeal carcinoma (NPC). Approximately 60-
70 % of the patients showed partial response, while the other 15-25 %
showed no response. Residual tumors are often found in patients who
receive cisplatin-based regimen. This clinical resistance is generally un-
desirable because it may develop into a tumor recurrence and poor
prognosis. Some researchers proved that such cases were due to the
cancer stem cell.
Aim This study was conducted to reveal the mechanism of NPC stem
cell resistance to cisplatin through expression of CD44, Hsp70, p53
(wild type), Oct-4, and ß-catenin encoded-genes.
Method The study was an in vitro experimental laboratory, carried
out through four stages: 1) isolation and culture of NPC stem cells
obtained from the biopsies of NPC patients; 2) characterization of
NPC stem cells (CD44+); 3) determination of the concentration of cis-
platin used in the study; and 4) analysis of NPC stem cell resistance
to cisplatin. The statistical analysis was performed using ANOVA.
Results and discussion After administration of cisplatin the expres-
sion of the encoded-genes was significantly increased (CD44, p <
0.0001, Hsp70, p < 0.0001, Oct-4, p = 0.003, and p53 (wild type), p =
0.000); but not ß-catenin (p = 0.270). Furthermore, through regression
analysis it was shown that Hsp70 (p = 0.002) and CD44 (p = 0.029)
were strongly affected the cell death. This study suggested that the
increasing expression of CD44, Hsp70, p53 (wild type), and Oct-4 in-
fluenced NPC stem cell resistance to cisplatin.
P1
Prevalence of nasopharyngeal carcinoma patients at Departement
of Otorhinolaringology-Head and Neck Surgery, Dr. Hasan Sadikin
general hospital, Bandung, Indonesia in 2010-2014
Deasy Z Madani, Nur Akbar, Agung Dinasti Permana
Department of Otorhinolaringology-Head and Neck Surgery, Faculty of
Medicine, Padjajaran University/Dr.Hasan Sadikin General Hospital,
Bandung, Indonesia
Correspondence: Deasy Z Madani (deasymadani@gmail.com) –
Department of Otorhinolaringology-Head and Neck Surgery, Faculty of
Medicine, Padjajaran University/Dr.Hasan Sadikin General Hospital,
Bandung, Indonesia
BMC Proceedings 2016, 10(Suppl 1):P1
Introduction Nasopharyngeal carcinoma is a disease with a certain
geographical and ethnic distribution around the world.
Aim The present study aimed to determine the prevalence of patients
with nasopharyngeal carcinoma presenting at the Otorhinolaringology-
Head and Neck Department, Dr. Hasan Sadikin General Hospital
Bandung between 2010-2014.Methods A descriptive analysis with sampling method was con-
ducted on data of NPC patients from medical records at Dr. Hasan
Sadikin General Hospital Bandung between 2010-2014.
Results and discussion Total patient visits at the Otorhinolaringology-
Head and Neck Surgery Department, Dr. Hasan Sadikin General Hos-
pital Bandung in the period was 2250. From a total of 692 patients with
NPC, 426 data were included, comprising of 265 males and 161 fe-
males. Most subjects were of elementary school background (45 %)
and with a peak age group of 46-55 years (29.6 %). Most subjects were
male (62 %) with a diverse work background, while most females were
housewives (38 %). The most histopathology type was undifferentiated
carcinoma (57.3 %).
Conclusion and suggestion Local NPC patients were dominated by
individuals with middle age, older men, lower educational background
and tumors with undifferentiated type.P2
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Introduction NPC is rare, accounting for only 1-3 % of all pediatric
malignancies. Its incidence varies widely in different regions, reflect-
ing interactions between genetic and environmental factors.
Aims To describe clinical characteristic and environmental exposures
of two pediatric NPC cases.
Methods Case report.
Result We reported two cases from Dr. Sardjito Hospital Yogyakarta,
Indonesia recruited in 2014. A 10-year-old boy and a 12-year-old girl
have already visited general practitioners several times with flu-like
complaints. After several unsuccessful attempts at medication, visible
lumps in the neck then appeared and they were referred to Dr. Sard-
jito Hospital. Flexible nasal endoscopy for both patients showed soft
tissue masses in the nasopharynx. Histopathology examination re-
vealed undifferentiated carcinoma. The stages were T3N3aM0 and
T3N2M0. From the questionnaire given to the parents, it was shown
that both patients had high consumption of instant noodles, grilled
food, preserved meat, and soy sauce. Additionally, on a daily basis,
the boy was exposed to burning firewood and was a passive smoker,
while the girl was exposed to wood dust and the use of insecticide
spray at home on a daily basis. IgA-EBV ELISA showed that results of
both childrens’ parents and the boy were below cut off (< 0.41), but
not the girl (0.84).
Future plan To collect more data about NPC in children, either clin-
ical presentation or epidemiology aspect to identify risk factors, as
well as improving awareness on unspecified complaint among chil-
dren to find early onset of NPC.
Consent to publish
Written informed consent for publication of this clinical details and/
or clinical images was obtained from the patient/parent/guardian/
relative of the patient. A copy of the consent form is available for re-
view by the Editor of this journal.
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Introduction Concurrent chemo-radiation therapy (CCRT) showed a
significant improvement in disease control and clinical outcome in
patients with nasopharyngeal carcinoma (NPC) with locoregional ad-
vanced disease. Effective induction chemotherapy has the potential
to downsize locoregional disease prior to definitive treatment.
Aim This study aimed to analyze the survival rate of NPC patients
who received induction chemotherapy followed by CCRT.
Methods An observational study was conducted on data of NPC pa-
tients diagnosed at the local setting between January 2007 and De-
cember 2011 with stage II-IVB. Twelve out of 16 (75 %) patients
completed 1st-line treatment schedule of induction chemotherapy
with docetaxel, cisplatin and 5-FU (TPF) 3 cycles followed by CCRT
with carboplatin 1.5 AUC day 1 and concurrent radiotherapy in day
1-5 weekly for 7 cycles.
Results The median age was 51.5 (37-71) years. All cases had WHO
type III pathology features and 8 (66.7 %) patients had bilateral en-
largement masses. Most of cases were males (10, 83.3 %). The me-
dian of body mass index (BMI) was 22.5 (15.7-27.5). There were 4
(33.3 %) cases with stage II-III and 8 (66.7 %) cases with stage IVA-
IVB. Three-year survival rate of cases was 33.3 %. The frequency of
patients achieving three-year survival was more frequent in females
compared to males (50 % vs 30 %, p = 0.570), in patients with BMI ≤
22.5 compared to >22.5 (50 % vs 16.67 %, p = 0.270), and in patients
with stage II-III compared to IVA-IVB (50 % vs 25 %, p = 0.400).
Conclusion In local patients receiving induction chemotherapy fol-
lowed by CCRT, three- year survival was more frequently achieved by
females, individuals with BMI ≤22.5 and stage II-III, even though no stat-
istical significance reached.
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male patients was significantly higher than in female. Several studies
showed sex and age have strong influence on a patient’s survival in
solid tumor. Their prognostic impact in NPC patients remains unclear.
Aim To investigate the effect of sex and age difference on overall
survival and clinical outcomes of NPC patients.
Methods A retrospective study included data of NPC patients at Dr.
Sardjito Hospital between 2007-2011. From 333 NPC patients, 10
were excluded due to incomplete information of histopathology
data. Kaplan-Meier and cox regression method were used to calcu-
late overall survival (OS). Kruskal-Wallis analysis was used to define
the relationship among variables.
Results and discussion Male patients were two-fold higher in fre-
quency than female patients (225, 9.7 % and 98, 30.3 %, respectively).
Female patients had a higher median OS compared with male patients
(2.62 years versus 1.24 years; hazard ratio for male patients 1.271), al-
though no statistical significance was reached (p = 0.286). It may be
caused by the difference of tumor behavior between male and female
that was influenced by their different genotype and hormonal function.
The frequency of NPC was higher in older patients (≥ 45 years) than
younger patients (<45 years) (62.6 % versus 37.4 %). Older cases had a
significant lower median OS (1.45 years versus 2.51 years, hazard ratio
for older patients 1.727; p = 0.014). The correlation between age and
OS was stronger in male patients (p = 0.010) than in female patients
(p = 0.577). Compared to younger patients, older patients had more
comorbidities and poorer baseline characteristics such as anemia
(p = 0.106) and low creatinine clearance (p = 0.390). They also experi-
enced more adverse reactions during treatment course including myelo-
suppression (p = 0.004), nephrotoxicity (p = 0.007), electrolyte disturbance
(p = 0.008), diarrhea (p = 0.006), and nausea and vomiting (p = 0.050)
that might contribute to the lower OS. Multivariate analysis showed
that age was an independent prognostic factor for the OS (p = 0.014).
Conclusion Male NPC patients and cases with older age had a lower
OS compared to their counterparts. Furthermore, older age was a
negative independent prognostic factor for the survival.P5
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Introduction Nasopharyngeal carcinoma (NPC) is the most common
malignancy of head and neck in Indonesia. Early detection is difficult
and early diagnosis and treatment are frequently delayed.
Aim This study evaluated presentation and treatment outcomes of
patients with NPC who had delayed diagnosis and therapy in a ter-
tiary referral centre, in Yogyakarta, Indonesia.
Methods One-hundred and three patients diagnosed as NPC between
2007 and 2011 were retrospectively evaluated. Baseline data included
age, gender, type of insurance, disease stage, presenting symptoms,
symptom-to-visit interval (SVI), and diagnosis-to-treatment interval
(DTI). Treatment outcomes and overall survival (OS) were analyzed.
BMC Proceedings 2016, Volume 10 Suppl 1 Page 18 of 24Results and discussion Of 103 patients, 87 (94.1 %) had an advanced
disease, 23 (22.3 %) had distant metastases, and 48 (46.6 %) pre-
sented with neck mass as early symptoms. The mean of SVI was
9.9 months and the mean DTI of was 53 days. From 53 patients hav-
ing SVI more than 6 months, 22 (41.5 %) were with low education,
covered by government insurance for the poor people (28, 52.8 %),
lived outside of Yogyakarta (31, 58.5 %) and had neck mass as early
symptoms (27, 50.9 %). Out of 105 patients planned for first line
treatment, 22 patients did not complete the treatment due to death
(2, 1.9 %), adverse event (1, 1 %), financial problems (1, 1 %), lost to
follow up (16, 15.2 %) and unknown reason (2, 1.9 %). In 83 patients
who completed the treatment, only 49 records of treatment response
were available. Complete response was achieved in 10 patient
(20.4 %) and partial response in 11 patients (22.4 %). Twenty patients
(40.8 %) were in stable disease while 8 patients (16.3 %) showed dis-
ease progression. Median of OS was 17.23 months (ranged from 0.7-
60.9 months) and 3-year survival rate was 16.5 %.
Conclusion and future direction Treatment outcomes in NPC pa-
tients who had delayed diagnosis and therapy was poor. Level of
education, health insurance coverage, distance from referral centre,
and non-specific early sign of NPC may contribute to the delay of
SVI. The practitioners must improve their capabilities in educating pa-
tient for symptoms of NPC so that cases with earlier stage can be
identified. Furthermore, patients should be better educated about
the importance of immediate treatment initiation in order to achieve
optimum results.P6
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Introduction Neoadjuvant therapy with cisplatin and 5-fluorouracyl
(5-FU) has been a reasonable treatment option for advanced naso-
pharyngeal cancer (NPC) in regions where delayed radiotherapy initi-
ation is relatively common, such as Yogyakarta. As pretreatment
anemia has been observed to negatively influence patient’s survival
in various cancers, the present study analyzed its impact in NPC pa-
tients undergoing neoadjuvant treatment.
Aim This study aimed to determine whether pretreatment anemia has
a prognostic role in NPC patients undergoing neoadjuvant therapy.
Methods The data of 40 patients diagnosed as NPC between January
2007 and December 2011 and who underwent neoadjuvant therapy
with cisplatin and 5-FU were retrospectively reviewed. Baseline
hemoglobin concentration were evaluated at diagnosis. Hemoglobin
concentration of less 13 g/dL for males and less than 12 g/dL for fe-
males were defined as anemia. Along with other known prognostic
factors (age and sex), the prognostic value of pretreatment anemia
was analyzed. Overall survival (OS) was assessed using the Kaplan-
Meier method. Univariate analyses was used to evaluate prognostic
significance.Results Pretreatment anemia was observed in 12 (30 %) patients.
Median OS was 32.2 months (ranged from 28.2-37.5 months). Pa-
tients with pretreatment anemia showed significantly lower median
OS than those with normal hemoglobin concentration (21.3 vs
34.5 months, p = 0.044). In univariate analysis, cases with pretreat-
ment anemia had lower median OS, although significance was not
reached (HR = 2.68; 95 % confidence interval 0.98-7.28).
Conclusion Local NPC patients who underwent neoadjuvant therapy
and had pretreatment anemia showed a worse median OS compared
to those without anemia. However, the pretreatment condition did
not significantly predicted patient’s survival.P7
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Introduction The significance of the problem of radiotherapy wait-
ing lists in local patients has been documented. Delays in initiating
radiation treatment may result in poorer treatment outcomes. Even
though neoadjuvant chemotherapy had not been considered a
standard approach for locally advanced nasopharyngeal carcinoma
(NPC), it may be given while waiting for the radiotherapy schedule.
The platinum-based chemotherapy combined with 5-fluorouracil
(5-FU) was the most frequently used for NPC. Data on NPC pa-
tients receiving neoadjuvant cisplatin 5-FU chemotherapy followed
by radiotherapy at our cancer clinic had not been comprehensively
analyzed.
Aim To analyze the survival rate of NPC patients who received neo-
adjuvant cisplatin-5-FU chemotherapy followed by radiotherapy.
Methods An observational study was conducted on data of NPC pa-
tients diagnosed at Dr Sardjito Hospital Yogyakarta between January
2007 and December 2011. Patients with stage IIB-IVB disease who re-
ceived cisplatin IV infusion 100 mg/m2 on day 1 and 5-FU IV infusion
1000 mg/m2/24 hours on days 1 to 4, or 1 to 5 as neoadjuvant ther-
apy were analyzed.
Results Fourty-three (n = 43) stage IIB-IVB NPC were analyzed. The
age of subjects ranged from 17 to 76 years (median 48 years),
with male predominant (67.40 %). Stage III, IVA, and IVB were 17
(39.54 %), 6 (13.95 %) and 20 (46.51 %) subjects, respecively.
WHO type III was predominant (95.35 % cases). The radiation dose
ranged from 18 to 70 Gy (median 66 Gy). A total of 37 (86.05 %)
subjects received 3 cycles of cisplatin-5FU, while 4 (9.31 %) re-
ceived 4-6 cycles and 2 (4.64 %) received 1 cycle only. The median
survival was 34.63 months. The 3 year- and 5 year-survival rates
were 45.30 % and 37.80 %, respectively. The median follow up
period was 23.27 months. When compared, stage III and IV sub-
jects had similar median survival (36.50 months versus 33.93 months,
p = 0.295).
Conclusion With neoadjuvant cisplatin and 5-FU, survival beyond
5 years was possible in our local setting. Treatment adherence, pa-
tient’s obedience on follow up, and improved radiologic facilities
may contribute to a better survival rate.
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Introduction Aging patients with cancer commonly pose special
problems. As a special population of cancer patients, they may have
specific clinical features and treatment outcomes.
Aim To explore the database of nasopharyngeal cancer (NPC) geriat-
ric patients in the local centre, regarding the specific clinical features
and the treatment outcomes.
Methods Retrospective analysis was done on data of NPC patients di-
agnosed between 2007-2011 at Dr Sardjito Hospital, Yogyakarta
Indonesia (organ-specific cancer registry). Geriatric patients were de-
fined as cases of ≥60 years old at first visits. The effect of age and
treatment on patients’ survival were analyzed.
Result and discussion During the period, data from 65 geriatric NPC
patients were recorded in the database. Mean age was 66.6 years old
(range 60-85 years old). The majority of patients presented at late
stage of the disease (89.2 % in stage III or IV). The median time of
‘symptom-to-first-visit’ was 6 months. The active cancer treatments
(chemoradiation or chemotherapy alone) were given to 45 (67 %) pa-
tients. The adherence for completion of the planned treatments was
60 %. Non-adherence (33 %) was due to lost to follow up. The rate
of 1-year survival was 32 %. There was no significant difference
found between the survivors and the non-survivors (p = 0.406, Mann-
Whitney test), as well as Karnofsky performance status (p = 0.943,
Mann-Whitney test). There was a slight association between active
treatment and survival in one year (p = 0.047, Chi-square), although
this trend was not maintained in survival analysis (p = 0.182, log-rank
test). ‘Late-stage presentation’ was apparently the main problem in
geriatric NPC patients, putting them in the commonly incurable
stage of the disease, associated with low survival rate. A comprehen-
sive strategy for disease down-staging, beside active treatments, may
serve as a better management approach.P9
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Introduction Nasopharyngeal cancer (NPC) is radiosensitive and che-
mosensitive. However, the response to cisplatin chemoradiation for
an individual patient is unpredictable. The lack of factors to predict
the treatment response remains a major problem. Elevated lympho-
cyte to monocyte ratio (LMR) and neutrophil to lymphocyte (NLR)
has been reported to be associated with prognosis in NPC.Aim The aim of this study was to investigate the correlation of LMR
and NLR to complement as predictor in the assessment of response
to cisplatin chemoradiation in NPC.
Methods We collected data from a prospective cohort study in Dr
Hasan Sadikin General Hospital, Bandung. The study was performed
from October 2012 to October 2013. Clinical examination and CT
scan were performed before and after chemoradiation to determine
the therapy response based on Response Evaluation Criteria in Solid
Tumors (RECIST) criteria. The relationship between treatment re-
sponse and pretreatment LMR and NLR was analyzed using point bi
serial correlation test.
Result and discussion We enrolled 35 patients, and 5 were excluded
from the study due to incomplete treatment. Thirteen (13) out of 30
patients were at stage IVA and 17 patients were at stage IVB. There
were 23 (76 %) responder patients (1 patient with complete, 1 stable
and 21 partial response), and 7 (24 %) unresponder patients (with
progressive disease). NLR was significantly correlated with response
of cisplatin chemoradiation in patients with locally advanced NPC
(r = -0.330; p = 0.037), but not LMR (r = -0.171, p = 0.187).
Conclusion In locally advanced NPC patients who were treated with
cisplatin chemoradiation, NLR may be a predictive factor, but not
LMR.
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Introduction Epstein-Barr virus (EBV) infection is known to be associ-
ated with the development of nasopharyngeal carcinoma (NPC). Co-
factors include long-term cigarette smoking, family history and diet
marker. The evaluation of EBV markers and other risk factors may
help in future identification of risks. However, it is still unclear
whether EBV alone or combined with other risk factors is sufficientfor
NPC riskprediction.
Aims This study aims to assess the predictability of NPC risk using a
case-control study by evaluating the combination of anti-EBV markers
with and without known environmental factors.
Methods A case-control study was conducted in Taiwan. A total of 699
histologically confirmed incident NPC cases and 1,359 controls fre-
quency matched to cases on sex, age were recruited between July
2010 and December 2014.A questionnaire inquiring socio-demographic
characteristics, cigarette smoking, diet consumption, family history of
BMC Proceedings 2016, Volume 10 Suppl 1 Page 20 of 24NPC was used in the trained nurse interview. Blood specimens were
tested for anti-EBV VCA IgA and anti-EBV EA-EBNA1 IgA. The predictive
accuracy and 95 % confidence interval (CI) was evaluated using the
area under the receiver operating characteristic curve (AUROC). Several
risk models were used to combine different sets of NPC predictors.
Result and discussion The AUROC model predicted NPC poorly
based on only environmental factors (AUROC = 0.647, 95 % CI =
0.622-0.673) and NPC family history (AUROC = 0.544, 95 % CI = 0.530-
0.559). The corresponding AUROCs (95 % CI) were 0.885 (0.870-0.900)
and 0.911 (0.897-0.924) for anti-EBV VCA IgA and anti-EBV EA-EBNA1
IgA, respectively. The AUROCs (95 % CI) were 0.912 (0.897-0.926) for
anti-EBV VCA IgA and 0.936 (0.924-0.948) for anti-EBV EA-EBNA1 IgA
after adjusting for family history and environmental factors. Anti-EBV
marker and other factors may be combined into useful risk models
for predicting NPC risk. Additional analyses are on going.
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Introduction Nasopharyngeal carcinoma (NPC) is a unique cancer
with incidence which varies widely according to geographic location
and ethnic background. Many studies have shown that the etiology
of NPC is multifactorial, including genetic, viral infection and envi-
ronmental factors. NPC is a frequent cancer in Indonesia, and, specif-
ically, the most common head and neck cancer in West Sumatra.
Indonesia has diverse ethnic groups with various lifestyles and local
food. Minangkabau is an ethnic group that dominates the population
of West Sumatra.
Aims This study aimed to determine whether non-viral factors in-
creased the risk of NPC in this population.
Methods A case-control study was conducted in 33 newly diagnosed
NPC cases and 33 sex- and age- (±5 years) matched controls. Data were
collected for demographic characteristics and exogenous factors using
questionnaire through face to face interviews. Odds ratio (ORs) and cor-
responding 95 % confidence intervals (CIs) were estimated.
Results and discussion The present study demonstrated that expos-
ure to smoke of anti-mosquito coils (OR = 3.54; 95 % CI 1.28-9.80), ex-
posure to wood dust (OR = 3.63; 95 % CI 1.02-12.93), and family
history of NPC (OR = 2.06; 95 % CI 1.60-2.66) were associated with an
increased risk of NPC. Salted fish consumption was more frequent in
cases than controls, but the difference was not significant (OR = 2.51;
95 % CI 0.90-7.00). There were no associations between NPC risk and
preserved meat (OR = 3.20; 95 % CI 0.31-32.47), tobacco smoking
(OR = 2.37; 95 % CI 0.88-6.35), alcohol consumption (OR = 1.24; 95 %
CI 0.34-4.56), wood fire (OR = 2.30; 95 % CI 0.80-6.60), herbal medi-
cine (OR = 0.31; 95 % CI 0.31-3.17), past history of chronic disease in
ear, nose, and throat (OR = 1.69; 95 % CI 0.52-544) and pesticides ex-
posure (OR = 2.60; 95 % CI 0.91-7.44).
Conclusion Our results suggested that the use of anti-mosquito coils
and exposure to wood dust are associated with the risk of NPC de-
velopment in the West Sumatra population.
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BMC Proceedings 2016, 10(Suppl 1):P12Introduction Nasopharyngeal Cancer (NPC) is also named “Guang-
dong cancer”, a rare malignant tumour with most incidence in five
southern Chinese provinces (population in 2013: 2.4 billion). NPC
diagnosis is usually made by nasopharyngoscopy and biopsy at ad-
vanced stage, when the cancer seriously impacts the clinical out-
come and the patient quality of life. Earlier diagnosis of concerned
population in endemic areas is an important unmet need. EBV IgA
biomarkers are currently used for screening.
Aims The aim of the study was to evaluate the performance of a
new prototype automated VIDAS® EBV IgA tests for the screening of
the patient with NPC.
Materials and methods Characterized samples coming from Ghangzhou,
China (NPC patients (N = 150) and controls (N = 150)) and coming from
Casablanca, Morocco (NPC patients (N = 67) and controls (N = 100)) are
tested with the new Vidas prototype.
Results and discussion On characterized sera samples, the sensitiv-
ities of VIDAS EBV IgA, on Chinese samples, on Moroccan samples
and globally were respectively 93.3 % (88.1 %-96.8 %), 86.6 % (76.0-
93.7) and 91.5 % (86.7-94.7) and the specificities of VIDAS EBV IgA on
Chinese samples, on Moroccan samples and globally were respect-
ively 91.1 %(85.5-95.0), 92.0 %(84.8- 96.5) and 91.4 % (87.3-94.6). The
new Vidas EBV IgA prototype can give a result in 25 minutes using
the automated Vidas system. The new VIDAS EBV IgA quick pre-
sented good performance in accordance with the patients’ clinical
status. VIDAS EBV reagents will be a good alternative enabling single
testing as well as series to currently used manual method for NPC
diagnosis.P13
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Introduction Distant metastasis after treatment is common in naso-
pharyngeal cancer (NPC). There are no pre-treatment predictors and
early markers for effective treatment response monitoring.
Aims This study aimed to evaluate the expression of Epstein-Barr
Virus (EBV) latent membrane protein-1 (LMP1) and vascular endothe-
lial growth factor (VEGF) as predictors and plasma EBV-DNA levels as
early markers of distant metastasis after treatment.
Methods A case-control study was done on patients who had and
did not have distant metastasis after therapy. The study was conducted
in Dharmais Cancer Center and Cipto Mangunkusumo Hospitals,
Jakarta, between January 2006 and December 2007. The expression of
EBV-LMP1 and VEGF were done by immunohistochemistry from naso-
pharyngeal biopsy specimens at diagnosis, whereas plasma EBV-DNA
was assayed from the patients’ blood, six months after therapy and
was quantified using RT-PCR technique.
Results and discussion A total of 53 patients were enrolled in this
study; 40 (75 %) of them were men. Patients’ mean age was 49 years.
There were 22 (41.5 %) patients with distant metastasis and 31
(58.5 %) patients without distant metastasis after treatment. Mean
score of EBV-LMP1 and VEGF expressions were significantly higher in
patients with distant metastasis compared to patient without distant
metastasis. Measurement of plasma EBV-DNA levels had 95.2 % sen-
sitivity, 96.6 % specificity, and an AUC of 0.962 (95 % CI 0.902-1.023)
to detect early treatment failure.
Conclusion and suggestion The expression of EBV-LMP1 immuno-
histologically has a bigger effect than VEGF expression and can be
used as predictor for distant metastasis after treatment and there-
fore should be evaluated at the time of diagnosis. Plasma EBV-DNA
level after therapy is highly sensitive as early detection for distant
failure and should be done periodically for monitoring the treat-
ment response.
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Introduction In an epidemiology survey, data samples can be ob-
tained through questionnaires as well as biosample retrieval. How-
ever, subjects who are willing to participate in surveys often refuse
to give their biosample.
Aim This research aimed to identify the characteristics and factors in-
fluencing subjects’ refusal towards peripheral blood sampling on a
hospital-based case-control study in Yogyakarta.
Methods Analysis was done using analytical descriptive method with
cross sectional design. The subjects were controls from hospital-
based NPC case-control study in Dr. Sardjito Hospital Yogyakarta
(n = 277) recruited in 2014. Demographic questionnaire and per-
ipheral blood sampling were taken at the same time. The differ-
ence of population characteristics were observed using chi square
with two tails p value ≤ 0.05 regarded as significant.
Results All subjects could answer the questionnaire well. Male:female
ratio was 3.1:1, with the highest age group of 50-60 years old
(23.1 %). The highest level of education was university level
(35 %). As much as 37.2 % of the respondents were willing to
have their peripheral blood sampled. This group was dominated
by males (71.8 %), individuals of 31-40 years (28.2 %), and gradu-
ated from university (45.6 %). Among those who refused to have
their peripheral blood sampled, only 3.4 % said that they were
scared of the procedure. The analysis showed that the lower the
level of education and the older the age, the higher the rejection
for the peripheral blood sampling (p = 0.008 and p = 0.045). In
addition, for the blood sampling methods, people with high level
of education tended to choose fingerprick compared to blood
drawning from the vein (p = 0.001), as they thought that the result
would be the same.
Future plan Different approaches among different age group and
educational background should be applied in order to educate sub-
jects and avoid rejection of participating in epidemiology survey.
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Introduction Nasopharyngeal Carcinoma (NPC) is an epithelial
associated-Epstein-Barr Virus (EBV) infected cancer which has be-
come an epidemic in the Asia region including Indonesia. Recently,
the incidence and mortality of NPC cases increased, and there is ten-
dency towards younger ages. The poor diagnostic method for thiscancer is one of the main problems for NPC treatment, thus new
efficient and effective diagnostic methods are needed. MicroRNA
BART-7 is one of the BART family microRNA that is expressed by EBV.
MicroRNA BART-7 is observed as one of the potential biomarkers for
the detection of NPC. Phosphatase and tensin homolog (PTEN) is a hu-
man tumor suppressor protein which associated to developments of
various types of cancer, including NPC. Mutation and deletion of
PTEN gene cause enzimatic inactivation of PTEN protein and lost of
tumor suppresion ability of PTEN. MicroRNA BART-7-3p is one of the
miRNA that targeted PTEN.
Aims This research aims to analyze the expression of MicroRNA
BART-7-3p and mRNA PTEN on NPC patient and healthy control.
Methods Analysis was performed on 64 plasma of NPC patients, 10
plasma of healthy control and 4 tissues of NPC patients by isolation
of total RNA, cDNA synthesis and quantification by qPCR.
Result and discussion The expression of MicroRNA BART-7-3p on the
plasma NPC patients were higher than the healthy control. On the
NPC tissues, the expression of MicroRNA BART-7-3p were very high
compared to the plasma healthy control. Additionally, this research
also did the measurement of mRNA PTEN which is targeted by
MicroRNA BART-7-3p. The expression of mRNA on the plasma NPC
patients were lower than the healthy control. Through statistical ana-
lysis it was deemed that MicroRNA BART-7-3p and mRNA PTEN has a
negative correlation.
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Introduction Nasopharyngeal carcinoma (NPC) is one of Epstein-Barr
virus (EBV) associated malignancy, as observed in the presence of
antibody responses to EBV antigens. Development of EBV-based
serological tool is important. However, NPC subjects recognize mul-
tiple EBV antigens, which require evaluation upon development of
an EBV-based diagnostic method using ELISA.
Aims To examine the potential of IgA against native EA protein
(IgA-EAext) as diagnostic and screening tool, either single or in com-
bination with IgA-[EBNA1 + VCAp18] response.
Methods A hundred and twenty (n = 120) histopathologicaly con-
firmed NPC patients and healthy population were tested to asses the
IgA-EAext response using ELISA method. The mean of IgA-EAext re-
sponses were tested using independent T-test. Kendall’s concordance
test was used to examine the concordance between IgA-EAext and
IgA-[EBNA1 + VCAp18] responses. Cut off value (CoV), sensitivity, spe-
cificity were determined by using ROC analysis, and also to calculate
the positive predictive value (PPV) and negative predictive value
(NPV) of IgA-EAext.
Result and discussion CoV of IgA-EAext ELISA was 0.274. Approxi-
mately 90.76 % (108/119) of NPC patients showed result above CoV;
while only 2.5 % (3/120) of healthy individuals showed positive re-
sult. The sensitivity, specificity, PPV and NPV of IgA-EAext were
90.76 %, 97.50 %, 97.29 % and 91.4 %, respectively. When the IgA-
EAext combined with IgA-[EBNA1 + VCAp18], the sensitivity became
lower (86.55 %) but the specificity reached 100 %, with PPV and NPV
were 100 %, and 88.23 %, respectively.
Conclusion IgA-EAext ELISA is a potential method for NPC diagnosis/
screening. When combined with IgA-[EBNA1 + VCAp18] these method
can be used as confirmatory test for NPC.
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Introduction Nasopharyngeal carcinoma (NPC) is the second most
common malignancy in Indonesia. Most of the cases are WHO III, of
which almost 100 % are related to EBV infection. Most of NPC pa-
tients are diagnosed at the late stage (III-IV), with therapy failure as a
consequence. Therefore, early diagnosis in high-risk population is
needed. In order to develop a reliable test for early diagnosis, EBV-EA
synthetic peptides were used as an antigen to detect IgA antibodies
using the ELISA method. The use of synthetic peptides was pro-
posed, due to its stability, it being easily produced and relatively
more economical compared to natural or recombinant antigen.
Aims To evaluate the diagnostic values of IgA responses against two
EA-p47/54 derived peptides (EA-1580 and EA-1582) by calculating
the sensitivity, specificity, positive predictive value (PPV) and nega-
tive predictive value (NPV).
Methods Plasma of NPC cases were obtained from archives of NPC
study at out institution (n = 100), while plasma from healthy control
were collected at regional blood bank in Yogyakarta, Indonesia in
2014 (n = 100). Iga-EA peptides test were done using indirect ELISA.
The difference response in both groups were analyzed using Mann-
Whitney test. ROC analysis used to determine the cut-off value (CoV)
in order to determine the sensitivity, specificity, PPV and NVP.
Result and discussion Mann-Whitney test showed that the IgA respon-
ses in both groups were significantly different (IgA-EA-1580 p value =
0.008; IgA EA-1582 p value = 0.026). The sensitivity, specificity, PPV and
NPV of IgA –EA-1580 and IgA-EA-1582 were 44 %, 98 %, 95.6 %, 36.4 %;
and 43 %, 97 %, 93.5 %, 63 %, respectively. These showed that capacity
of both IgA-EA peptides were similar for NPC diagnostic tool.
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Introduction Elevated titer of IgA-EBV is a hallmark of NPC. However,
previous studies in Yogyakarta showed that elevated IgA-EBV titer
was observed among >20 % healthy individuals either among un-
affected NPC families or non NPC familial individuals. Additionally,
the elevated IgA-EBV titer might be transient due to immunity or
other environmental factors, such as smoking habit.
Aims.To observe the association between smoking and IgA-EBV titer
among healthy individuals.
Methods A cross sectional study was done in 2013, recruiting donors
at local red cross unit. A self-filling questionnaire was used to obtain
demographic and smoking habit information. The smoking information
including smoking status, duration and numbers of cigarette smoked
per day were collected. Parallel peripheral blood samples were collec-
ted and tested for IgA-[EBNA1 + VCA-p18]-ELISA. Association betweensmoking habit and IgA-EBV titer was analyzed using logistic regression,
adjusted for age group and educational background.
Result and discussion Only males were included in this analysis (n =
240), with 47 subjects (19.60 %) had IgA-EBV titer above the ELISA
cut-off value (0.35). Ever smoker was associated with high level of
IgA-EBV (OR = 1.991; 95 % CI = 1.003-3.953). A dose response relation-
ship was observed in smoking duration (OR = 1.237 for 1-10 years;
OR = 1.954 for 11-20 years; OR = 3.637 for >20 years), smoking inten-
sity (OR = 1.733 for 1-10 cigs/d; OR = 2.732 for >10 cigs/d) and cumu-
lative number of cigarettes consumed (OR = 1.712 for 0.01-5.00 pack/
year; OR = 1.994 for >5.00 pack/year).
Conclusion This study demonstrated the association between smok-
ing habit and level of IgA-EBV titers in terms of duration, intensity,
and cumulative number of cigarettes.
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Introduction: Epstein-Barr virus infection is associated with NPC in en-
demic populations. A screening method has been developed by de-
tecting IgA-EBV among high risk groups such as healthy people with a
high level of IgA-EBV titer or first degree of NPC subjects.
Aims: To compare the distribution of IgA-EBV titer in non-family
healthy individuals and unaffected first degree family of NPC patients.
Methods: A cross sectional study among healthy blood donors (non
family) was conducted in 2013. Demographic data and parallel periph-
eral blood samples were collected and tested by using IgA-[EBNA1 +
VCA-p18]-ELISA. Distribution of IgA EBV titer was analyzed according to
sex, age, education level and compared to unaffected first degree
family of NPC patients (family; secondary data) using chi square with
two-tailed p value ≤ 0.05 considered as significant. Cut off value (CoV)
of IgA-[EBNA1 + VCA-p18] was determined at 0.35, and the value were
divided into four groups of≤ 0.35; 0.36-0.99; 1.00-1.99; and ≥ 2.00.
Results and discussions. We have analyzed 284 subjects from non
family and 508 family members. When comparing demographic dis-
tribution of non family and family, male : female ratio were 7.2:1 and
1:1; age below 40y were 80 % and 46.7 %; education below univer-
sity were 70 % and 91 %, respectively. Distribution of IgA-EBV titer
were 79.9 %; 13.4 %; 6.7 %; and 0 % for non family and 58.8 %;
26.8 %; 12.6 %; 2.4 % for family (p < 0.001). The differences were de-
termined by age group (p = 0.008) and education (p = 0.010).
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BMC Proceedings 2016, Volume 10 Suppl 1 Page 23 of 24Introduction IgA response to EBV antigen has been proposed for
nasopharyngeal cancer (NPC) serology based diagnosis and screen-
ing, especially Early Antigens (EA). Previous study showed that EA
antigen had a high response in NPC patients, and no other EBV-
related disease patients. Synthetic peptides have been proposed to
replace natural antigens, as they are small molecules, easy to pro-
duce, and more stable. Synthetic peptides have to be able to replace
EA epitope provided by the natural antigen.
Aims To identify six EA synthetic peptides for NPC diagnosis.
Methods Twenty (n = 20) NPC and healthy (n = 20) plasma samples
were used to observe IgA response to EA-1580 and EA-1582 (derived
from p47/54 protein sequence), EA-1579, EA-1101, EA-1102, and EA-
1104 (derived from p138 protein sequence) peptides. Statistic ana-
lysis were performed using Mann-Whitney U test with P ≤ 0.05
regarded as statistically significance.
Result and discussion Mann-Whitney U test on IgA-EA-1579, IgA-EA-
1580, IgA-EA-1582, IgA-EA-1101, IgA-EA-1102, and IgA-EA-1104 re-
sponse showed P value of p < 0.0001 (U = 4), p < 0.0001 (U = 71), p =
0.001 (U = 83), p = 0.253 (U = 157), p = 0.529 (U = 176), and p = 0.002
(U = 9 0), respectively. This indicated that EA peptides derived from
p138 protein sequence had the ability to differentiate healthy and
NPC population better compared to EA derived from p47/54 protein.
This merit further investigation to developed into diagnostic tool for
NPC diagnosis.P21
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Introduction Nasopharyngeal carcinoma (NPC) is geographically en-
demic in the world, with multifactorial causes. EBV infection has been
shown to consistently correlate with NPC, and is reflected by the ex-
pression of EBV latent and lytic genes. Particularly mRNA LMP1 could
be used as a biomarker for EBV latent infection, while mRNA BRLF1
as biomarker for EBV lytic infection. As related to infection, polymor-
phisms of TCRB host gene could be associated with the susceptibility
to NPC, particularly in the variable domain of TCR gene.
Aims The aims of this study were to determine firstly, the relative ex-
pression of mRNA BRLF1 EBV as a potential tumor progressivity bio-
marker in NPC, secondly, the polymorphisms of TCRBC and TCRGC2
host gene related to the genetic susceptibility of NPC.
Methods This reseach designed as cross sectional study. The sam-
ple was represented by 82 NPC patients at Tumor Division, ENT
Department, Dr. Cipto Mangunkusumo Hospital/Faculty of Medicine
Universitas Indonesia, Jakarta. The expression of mRNA LMP1 EBV
and that of mRNA BRLF1 EBV in NPC WHO-III patient were deter-
mined by RT-PCR technique. The relative expression of mRNA
BRLF1 EBV was analysed by RT-qPCR technique and further calcu-
lated by 2-ΔΔCt in NPC WHO-III patient who expressed mRNA LMP1
EBV and mRNA BRLF1 EBV.PCR-RFLP technique was done to deter-
mine TCRBC genotype (using BglII restriction site), while TCRGC2
genotype was identified by PCR-RFLP technique (using PvuII restric-
tion site) and nested Long-PCR technique (exon II triplication siteexisting). The distribution of TCRBC and that of TCRGC2 alotypes
were calculated from the genotype proportion.
Result and discussion The positivity of mRNA expression of LMP1 and
BRLF1 were 93,1 % and 65,2 %, respectively. The relative expression of
BRLF1 EBV mRNA in NPC WHO-III patients in M1 status (distant metasta-
ses) increased 9.2 times compared to Mo status (without distant metas-
tases) (n= 21; df = 1; p < 0,005). The relative expression of BRLF1 EBV
mRNA in NPC WHO-III patients in stadium IV-C increased 10.2 times.
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Introduction Current treatments for nasopharyngeal carcinoma (NPC)
are often associated with potential toxicities. This has prompted efforts
to find alternative sources. Aglaia, a genus of plants belonging to the
family Meliaceae, can be found primarily in the forests in tropical Asia.
Several species within the genus are known for the isolation of cyclo-
penta[b]benzofuran-flavaglines. Silvestrol and episilvestrol, members of
this class of compounds, are isolated from the twig, fruit, and bark of
Aglaia stellatopilosa, a species endemic to Borneo. In view of the excep-
tionally high incidence rate of NPC in the East Malaysian state of Sara-
wak particularly in the Bidayuh ethnic community, we decided to
evaluate the role of these compounds, isolated from the natural re-
sources of Borneo, for the treatment of a major cancer in Borneo itself.
Aim This work was carried out to study the inhibitory effects of sil-
vestrol and episilvestrol on proliferation of human NPC cells.
Methods Silvestrol and episilvestrol were isolated from the bark of
Aglaia stellatopilosa. Growth kinetics was monitored dynamically
using a real-time, impedance-based cell analyzer. Dose-response pro-
files were generated using a colorimetric cell viability assay. Apop-
tosis was evaluated by flow cytometry and high content analysis.
Flow cytometry was also performed to determine cell cycle distribu-
tion. Finally, the effects of combining silvestrol
or episilvestrol with cisplatin on NPC cells were studied.
Results and discussion Apoptosis was not observed in silvestrol- and
episilvestrol-treated NPC cells but cell cycle perturbation was evident
in NPC cells. Treatment with either compounds induced significant
increase in the percentage of cells in G2/M phase compared to con-
trols. Silvestrol or episilvestrol showed synergistic effects with cisplatin
in inhibiting the proliferation of NPC cells. Our findings suggest that sil-
vestrol and episilvestrol have anti-tumour activity in NPC cells. Further
studies should be carried out on the mechanisms of action of these
compounds in NPC and their potential as anti-NPC agents, particularly
in combination with cisplatin.
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BMC Proceedings 2016, Volume 10 Suppl 1 Page 24 of 24Introduction Nasopharyngeal carcinoma (NPC) is the fourth highest
malignancy in Indonesia. MicroRNA is a potential biomarker for NPC
early diagnosis. Previous studies indicated that miR-141 was oncomir,
that target PTEN mRNA. Both acted on cisplatin resistance.
Aims To determine the expression profile of miR-141 and mRNA
PTEN in blood plasma of nasopharyngeal carcinoma patients com-
pared to healthy controls. Additionally, we wanted to determine the
expression profile of miR-141 and PTEN mRNA in NPC patient prior
and post theraphy.
Methods The study was conducted by in silico prediction to analyze
the interaction of miR-141 with PTEN mRNA. Further laboratory re-
search analyzed the expression level of miR-141 and PTEN mRNA
compared to healthy controls. Expression analysis was performed
using qRT-PCR with miR-16 and beta-actin as reference genes. The
analysis of the relationship between miR-141 and PTEN mRNA was
done through the chi square test.Results and discussion Twenty-one samples (n = 21) out of 46 sam-
ples showed higher expression of miR-141. Expression of miR-141 in
the blood plasma of nasopharyngeal carcinoma patients increased
(up regulated) 1.49 times (p = 0.075, two-tailed t-test) compared to
healthy controls. PTEN mRNA expression decreased (down-regulated)
0.65 times in blood plasma of nasopharyngeal carcinoma patients
(p = 0.323, two-tailed t-test) compared to healthy controls. Correl-
ation between miR-141 and PTEN mRNA was detected (p = 0.001).
Expression of miR-141 in pre and post therapy patient was lower
(0.61 times, p = 0.090) and expression of PTEN mRNA in pre and
post therapy is down regulated (0.5, p = 0.090).Based on the results
of the study, we concluded that there is a relationship between
miR-141 with mRNA PTEN. The role of miR-141 as oncomir can sup-
press the expression of mRNA PTEN in post-transcriptional pro-
cesses. Decreasing mRNA PTEN in patient pre and post therapy
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